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Abstract 
Herpes simplex virus, which infects a majority of the population, remains a 
significant human pathogen for which no effective vaccine exists. Despite decades of 
intensive research, this virus has resisted numerous classical and cutting edge approaches. 
We can only hope that additional research into new vaccines ideas as well as the 
fundamentals of how the virus interacts with the immune system will someday lead to the 
design of an effective vaccine. The first part of this dissertation focuses on the virus and 
how it interacts with various immune cells in the body. HSV-1 exerts a number of 
influences on a number of key immune cells, especially dendritic cells. The overview 
goes on to fully describe these interactions, the nature of the immune response generated 
to the virus, as well as past and possible future vaccine strategies. The second part 
explores the use ofhsp70 and peptide as an effective vaccine candidate in the neonate, in 
which infection can lead to life threatening situations. Results suggest that hsp70 is an 
effective adjuvant in neonates. The third section examines the use of hsp70 and peptide 
as a mucosa! adjuvant in adult mice. These data also demonstrate that hsp70 can act as an 
potent mucosal adjuvant. The final section explores utilizing an anti-DNA antibody to 
enhance targeting of plasmid DNA to antigen presenting cells in order to improve 
immune responses. Results indicate that anti-DNA antibody enhances immune responses 
to plasmid encoded antigen. In all, we hope that these novel vaccine approaches may one 
day be used in humans to induce protective immune responses to HSV-1. 
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Part I. 
Background and Overview 
1 
Introduction 
Herpes simplex virus types 1 and 2 both represent significant human pathogens 
that infect a majority of the population. They should be controllable by vaccines, but 
despite notable effort, satisfactory vaccines remain unavailable. One hopes that 
fundamental studies of both the virus and how it interacts with the host will uncover clues 
useful for the design of effective prophylactic and therapeutic vaccines. This review 
focuses on host responses to the virus revealed in both animal models and human patient 
studies. 
Initial immune events and their consequences 
Initial invasion by pathogens is met by numerous components of innate defense. 
These may serve to curtail infection, but this outcome is probably uncommon with HSV 
unless the infecting dose is minimal. The caveat of such failure is that virus can gain 
access to sensory nerve endings, is transported to sensory ganglia and establishes latency 
or perhaps persistence. These events occur well before effector T cells or antibodies are 
induced. Hence, if sterile immunity is to be achieved against primary infection it must 
rely solely on innate immune defenses. Many components participate in innate immunity, 
but their respective roles against HSV have receive4 little attention. This may be because 
until recently we had few if any therapeutic options to manipulate them. However, there 
is now an expanding array of approaches that can activate aspects of innate immunity 
which could affect the course of infection and the pattern of immunity. Some of these 
have been tested against HSV infections in humans and animal models [ 1]. We also 
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realize that manipulating innate immune function may impact on the subsequent 
magnitude and quality of the adaptive immune response. This review discusses the major 
components of innate immunity that can be targeted perhaps for future modulation. 
Upon entry into the host infectious virus is exposed to numerous innate defenses. 
These include several humoral molecules as well as a number of cellular defenses. 
Recently, most mechanistic studies have focused on cellular components of defense, 
especially dendritic cells (DC) and to a lesser extent natural killer (NK) cells, 
macrophages, and neutrophils [2-4]. However, humoral factors may well be pivotal and 
likely curtail infection with low doses. The humoral factors involved include complement 
factors, lactoferrin, natural antibody, and of course interferons. Most studies involve the 
latter and are discussed later. A few key studies have evaluated the role of complement, 
of which the most compelling are the observations of the Friedman group [5]. They 
showed that the major glycoprotein gC of HSV bound to C3b, an important molecule in 
the complement cascade. Additionly, gC binding to C3b prevented the otherwise 
destructive effects of complement activation. In support of this idea, gC minus mutants 
were only pathogenic in C3 depleted animals [5]. Nevertheless, whether or not variations 
in C3 levels, which can occur during ·certain chronic diseases, are associated with 
increased susceptibility to HSV infection is not clear. However, it is known that mice 
unable to make C3 are notably more susceptible to infection than control animals [ 6]. 
Natural antibody is another humoral innate component that acts as a hindrance to 
certain infections which include HSV [7]. This antibody either acts to neutralize and so 
prevent infection or perhaps mediate antibody dependent cell mediated cytotoxicity 
(ADCC) (8]. 
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Support for a possible role for natural antibody mediated defense was reported by 
Deshpande et al [9]. They showed that µM-1- mice, which lack B cell-mediated immunity, 
were considerably more susceptible to HSV, but their resistance could be partially 
reconstituted by transfer of narve serum containing natural antibody. 
With regard to interferons, the story is complex as is the interferon system itself 
[ 1 O]. Herpes simplex virus infection does induce various interferon species and viral 
replication is inhibited by interferons. Plasmacytoid DC, upon exposure to HSV, produce 
an abundance of type I interferons, and this may be a major source of IFN-a [11]. 
Moreover, knockout mice lacking either the IFN-a or y receptor are extremely 
susceptible to infection [12,13]. Interferons are further discussed in a later section. 
Dendritic cells and HSV 
Dendritic cells (DC) are one of the first immune cells to interact with pathogens, 
including HSV-1. These specialized antigen presenting cells (APC) play a critical role in 
acquiring antigen, processing it, and presenting foreign epitopes ·on MHC Class I and II 
molecules in order to efficiently prime T cells. In addition, they also must serve as 
"sentinels" of the body, determining what type of immune response, if any, is needed to 
combat a potential pathogen. These "danger" signals are primarily orchestrated through 
Toll-like receptors, which possess the ability to recognize pathogen-associated molecular 
patterns. Examples of such patterns ( and the TLR that they bind) include peptidoglycan 
(TLR2), dsRNA (TLR3), LPS (TLR4), flagellin (TLR5), ssRNA (TLR7), and CpG 
methylated dsDNA (TLR9) [ 14]. Recent studies have emphasized that herpes viruses 
may provide ligands for certain TLRs and implied that interaction of such ligands with 
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TLRs on DC and perhaps other cells represents a pivotal event in viral pathogenesis. 
However, most observations have been made in vitro with purified and likely 
unphysiological concentrations of ligands. Studies have shown that gB protein of human 
CMV binds TLR2 [15], as does an unknown protein ofHSV [16]. HSV DNA is also 
known to bind TLR9 [17], although whether or not this is a significant event in vivo 
remains in doubt. Recently, plasmacytoid DC were shown in vitro to react to HSV-2 
DNA and secrete IFN-a; but in vivo studies were not performed [18]. Similarly, HSV-1 
DNA stimulated plasmacytoid DC to produce IFN-a upon exposure to HSV-1 via TLR9, 
but, surprisingly, the majority ofIFN-a came from other cell types, such as macrophages, 
in a TLR9 independent manner [ 17]. 
The outcome of initial interaction between viruses and DC influences the nature, 
magnitude, and quality of the adaptive immune response. IfDC are impaired in their 
ability to mature or properly prime T cells, a chronic infection or death of the host may 
ensue for some viruses [ 19]. We do not know, however, if HSV interaction with DC 
represents a pivotal event, particularly in vivo. Some have suggested that HSV infection 
impairs DC function by preventing maturation, thus serving to retard or even prevent 
immune induction [20]. The Lanzavecchia group also showed that infected DCs failed to 
upregulate costimulatory molecules, produce cytokines, and were not responsive to 
chemokines, a process crucial for migration to secondary lymphoid organs. Similarly, 
mature DCs infected in vitro with HSV-1 changed both their phenotype and their ability 
to stimulate T cells [21]. However, these in vitro data may have been overinterpreted, 
since DC themselves seem not to be a major target for HSV infection in vivo, and in the 
mouse may avoid direct infection [22]. Nevertheless, the type of interaction made 
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between HSV and DC may impact on the quality of the adaptive immune response made, 
but if and how this occurs in vivo needs to be proven. 
Some recent studies in the mouse have focused on DC, and shed light on early 
events in T cell immune induction. For example, it was assumed that Langerhans cells, a 
predominant sub-type of DC in the skin, are one of the first cells to contact HSV-1. This 
is followed by transport of virus by a now mature DC to the draining lymph node where 
T cell priming occurs [2]. However, the Carbone group, using footpad infection of mice, 
demonstrated that neither Langerhans cells (CD1 lc+CD205highCD8a10w)nor plasmacytoid 
DC (CDl lb+CDl lc+CD8a10w were responsible for priming of CDS+ T cells. Instead, a 
different and uncommon DC sub-population was responsible, the CD l lc +CD8a + DC 
[23,24]. It appears that these cells may not be directly infected by HSV, but instead 
acquire viral antigens from other cell types by a process referred to as cross-priming [25]. 
Cross-priming currently enjoys popularity among mouse immunologists, but whether or 
not the process is a major event in human T cell immune induction remains to be 
established. Moreover, whereas CDS+ DC may be the most effective T cell priming cells, 
it is likely that other cell types, especially abundant ones, can also participate. The 
situation could also be different at mucosa! entry sites from that reported in the skin. For 
instance, the Iwasaki lab reported that vaginal submucosal CD1 lb+CD8a-DC were 
responsible for the generation of protective Thl responses to HSV-2 infection [26]. 
Intravaginal infection led to rapid recruitment of these submucosal DC to the infected 
epithelium. Careful analysis of various DC populations from the draining lymph nodes 
revealed that only the CD 11 b + submucosal DCs, but not Langerhans cell-derived or 
6 
CD8a + DCs, presented viral antigens to CD4+ T cells and induced IFN-y secretion, an 
unanticipated role for this DC subset [26] . Moreover, no evidence of direct infection of 
the DC could be found [22]. 
In contrast, a recent study from the Katz group indicated that human myeloid DC 
in the skin do become infected by HSY [27]. Curiously, this was followed by both 
' ' '  
infected and uninfected cells maturing and presumably migrating to the draining lymph 
node. It also seemed that the viral component from infected cells responsible for the 
bystander activation of uninfected DC was gD. This also resulted in the release of type I 
interferon. They suggested that the stage is set for a race between the maturation and 
priming capacity of the DC and the ability of HSY to disrupt such events [27]. 
We may conclude that one or more subsets of DC do indeed play an important 
role in immunity to HSY. DC seem responsible for mediating some innate defense but 
are perhaps even more important for the influence they exert on the subsequent adaptive 
immune response. Manipulating the function of DC does represent a logical target for 
vaccine design. Some initial studies have shown promise in this regard. Thus, the 
Spraunce group and others demonstrated that the TLR 7 /8 agonists imiquimod and 
resiquimod showed some efficacy against the severity and frequency of herpetic disease 
in humans [28-30]. In mice as well, manipulating DC function with TLR ligands was 
shown to raise the barrier to infection. Thus, at least two groups have shown that the 
mucosal delivery of CpG motifs provides temporary protection against vaginal challenge 
with HSY [31,32]. These TLR9 activating compounds may also act as excellent 
adjuvants permitting mice at least to respond and make CDS+ T cell responses to peptide 
antigens [33]. 
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Assuming HSV under in vivo conditions does indeed infect DC, there are 
additional effects which the virus can exert on DC function. These relate to effects on the 
antigen-presenting machinery, the expression of costimulatory molecules involved in 
antigen presentation, as well as the production of immunomodulatory cytokines [34]. 
Indeed, the DC has become almost over-exposed by its avid followers. Comprehensive 
reviews on DC in relation to their influence on infectious disease have been published 
and should be consulted for the full story [2,34]. 
Role of NK and NKT cells in HSV infection 
These cell types are both considered to participate in the initial response to an 
infection. They can both act to recognize infected cells and kill them or release numerous 
cytokines that participate directly or indirectly in immune defense [3]. We have known 
since the pioneering studies of Lopez that NK cells influence susceptibility to HSV 
infection [35]. Most notably, susceptibility to severe herpes infection occurs in humans 
with genetic defects in the NK cell response [36], and in mice genetic susceptibility 
differences may be explained by NK cell functional differences [37], but details of this 
genetic control remain confused [38]. We know that the NK cell response, and perhaps 
also NKT cells, helps prevent initial infection, but for HSV it is not clear if the virus-NK 
cell interaction affects the pattern of subsequent adaptive immune response, as it clearly 
does in mouse CMV infection [39]. It has become quite evident that the NK cell system 
is diverse and that several phenotypic and some functional subsets exist [ 40]. The basis 
of the phenotypic diversity is explained by the multiple receptors expressed on NK cells, 
some of which are expressed on all NK cells and others limited to different subsets [ 40]. 
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The NK cell receptors fall into two major functional groups: inhibitory receptors and 
activating. The inhibitory receptors mainly recognize MHC proteins, and when such 
ligands are diminished, such as can occur on a virus infected or tumor cell, the inferior 
signal stimulation results in NK cell activation [ 40,41]. This "missing self' hypothesis 
could explain why HSV infected cells, which do down regulate MHC molecules, result in 
NK cell activation [ 42]. NK cells additionally express many activating receptors 
although little is currently known about the ligands for such receptors. One exciting 
story, however, involves the herpesvirus MCMV. Here it was shown that the CMV 
M157 protein bound to the activating receptor Ly-49H and mice strains encoding Ly-49H 
were resistant to infection [ 43]. It is not known if other herpesviruses such as HSV 
encode proteins that engage NK activating receptors, but doubtless the search for such 
molecules is ongoing. Conceivably, HSV could also interact with NK cells by acting as a 
ligand for TLR2 or TLR9, both of which are present on NK cells [ 44]. Thus, HSV is 
reported to present ligands for both TLRs [16,18]. 
It seems likely that the major function that NK cells play during the initial 
response is to act as a source of cytokines that impact on antiviral defense and immune 
induction. Thus, NK cells act as a major source ofIFN-y and a minor source of IL-12, 
and abundant production of each are an early event in HSV infection [ 45]. The release of 
IFN-y activates other cells, such as macrophages, and possesses potent antiviral 
properties. IL-12 is a critical cytokine involved in shaping adaptive immunity, tipping the 
response to Th 1 [ 46]. NK cells express other molecules involved in antiviral defense and 
immune induction, but they do not directly participate in antigen presentation. 
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Although the relevance of NK cells in HSV immunobiology has been somewhat 
neglected, recent studies addressed the contribution of NKT cells. These cells share 
identity markers (NK.1 .1 +) and function much like NK cells, but they additionally express 
a highly limited T cell receptor repertoire. Most cells in the mouse recognize the non­
peptide antigen a-galactosylceramide presented by the nonclassical MHC molecule 
CD 1 d. Mice deficient in CD 1 d have few if any NKT cells and show delayed clearance 
and increased mortality upon infection with HSV [ 47]. Other data also indicate that NKT 
cells contribute to defense against HSV. Rosenthal showed that mice deficient in IL-15, a 
critical factor for NKT cells, were highly susceptible to infection [ 48]. 
We can conclude that NK cells are important cells in HSV immunity but it is not 
yet evident how we can influence the function of these cells with ligands that target them. 
However, we anticipate that the topic will be receiving attention in the future, likely 
coming primarily from observations in the MCMV field. 
Neutrophils and Macrophages in HSV infection 
Both these cell types are prominent early participants in inflammatory reactions to 
HSV infection [ 49]. Older studies focused heavily on macrophages and showed that 
depleting such cells or impeding their function enhanced susceptibility to infection [50]. 
The macrophage has become a somewhat neglected cell in immunology and many of 
them have been renamed as a subset of DC. In the mouse, if not in man, stimulated 
macrophages can exert powerful antiviral effects by producing reactive radicals such as 
NO [ 51]. Accordingly, iNOS knockout mice showed enhanced susceptibility to infection 
with HSV-1 [52]. 
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Neutrophils also exert antiviral innate defense, and several groups have shown 
this in mouse systems [4,53]. Accordingly, if neutrophils are depleted by specific 
antibody mice show significantly enhanced susceptibility to infection [54,55]. How 
neutrophils exert their defense is not fully understood, but reactive radical production and 
the secretion of antiviral cytokines are suspected mechanisms. 
The role of adaptive immunity 
Observations in humans and studies in mouse model systems leave little doubt 
that acquired immunity is crucial to contain infection [ 56]. Thus, as mentioned, innate 
immunity can handicap the chance of infection, but if it proves unsuccessful removing 
the virus becomes primarily the task of the adaptive immune response. With regard to 
resolving primary infection, most would agree that T cells are crucial for this to occur. In 
fact, T cell defects, either acquired ( as occurs in AIDS), congenital, or constructed ( as in 
some mouse models), result in prolonged and severe infections [57]. In T cell deficient 
mice the outcome is usually lethal encephalitis [58]. The role of antibody in the control of 
primary infection is usually considered as minor, especially since this response occurs 
later in comparison to T cell induction and antibody-mediated immunity is largely 
directed at extracellular virus. However, older studies did emphasize that perhaps ADCC 
was an important participant in anti-viral defense [59]. More recently, however, the 
Friedman group has questioned this, since HSV, via gE and gl proteins (which act as 
viral Fey receptors), seems to have an evasive maneuver against antibody-mediated 
immunity [5]. 
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Antibody, however, is an important component to prevent infection. This was best 
illustrated in humans by the observation that vaginally delivered infants exposed to HSV-
2 were protected if they received maternal antibody [ 60]. Furthermore, there is good 
evidence that the presence of type common antibody induced by HSV-2 protects against 
HSV-1 infection, although the reverse situation seems not to have a prominent effect 
[61]. It is also well known that once infected with an HSV-1 strain, patients generally do 
not become infected with additional strains of the same type. This situation is most likely 
mediated by antibody. Protection of susceptible mucosa! surfaces from reinfection 
appears to be performed most efficiently by antibody as was shown by mouse studies 
[ 62,63]. However, mucosa! memory tends to be of less duration than systemic, so 
mucosa! surfaces tend to lose antibody -mediated protection at a faster rate in 
comparison to systemic immunity [62]. Nevertheless, also in support of a role for 
antibody is the evidence that the currently used GlaxoSmithKline (GSK) vaccine seems 
to protect females from infection, but not males [ 64]. Any vaccine designed to protect 
against HSV must be capable of inducing neutralizing antibody, preferably including 
mucosal antibody. 
Most of the focus on immunity mechanisms against HSV has been directed at T 
cell immunity. Since it has considerable implication vaccine design, effort over the years 
has gone into defining what aspects of T cell immunity dominate antiviral defense and 
how protection proceeds mechanistically. Several studies have been done in mice, a 
mixed blessing since the mouse can often convey a misleading message, particularly 
since this non-mouse pathogen shows several differences in pathogenesis. Mice are more 
likely to suffer from herpetic encephalitis upon infection, and curiously almost any form 
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of immunization c3:11 be contrived to protect them. In contrast, humans, fortunately, 
seldom succumb to encephalitis, but so far no vaccine seems able to protect them. Our 
understanding of human adaptive immunity to HSV comes largely from groups led by 
Corey in Seattle and Cunningham in Sydney. Both have written recent valuable reviews 
which cover the topic more comprehensively than the following summary saga [ 61,65]. 
Primary infection by HSV, if not successfully dampened by innate defenses, 
becomes clinical with lesions persisting up to 3 weeks and viral shedding lasting for 10 
days or so. During this time an adaptive immune response is being generated, but it may 
be retarded by HSV infecting DC, making such cells inferior APC [65]. Lesion cessation 
appears to be a consequence of both CD4+ and CDS+ T cell function. In the recurrent 
situation, which is better investigated since it is easier to study, things happen more 
quickly. Lesions last up to 10 days and viral shedding for around 4 days [66]. The issue 
has been why clinical lesions occur at all, since, invariably, latently infected patients 
retain circulating antibody and have memory CD4+ and CDS+ T cell immunity. 
Moreover, the extent of these immune parameters do not show significant differences in 
magnitude nor pattern from latently infected patients who never suffer recurrences [ 66]. 
However, when following the sequence of immunological events studied by serial 
biopsies of recurrent lesions a pattern emerges. It seems that CD4+ T cells, along with 
neutralizing antibody through leaky vessels, are the first to invade [56]. CD4+ T cells can 
be induced to produce an abundance of IFN-:y and other cytokines. 
CDS+ T cells invade later, but their arrival seems to coincide with infection 
control [56]. This has given rise to the notion that perhaps CDS+ T cells are principally 
responsible for resolution, an idea supported by the observation that the severity of 
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genital herpes in AIDS patients seemed to correlate pest with the magnitude of the CDS
+ 
T cell response [ 67]. However, it is by no means certain how the CD8+ T cells subserve 
their protective function. Thus, HSV infection of cells may cause them to downregulate 
MHC restricting molecules by a variety of mechanisms [42]. Moreover, the Jerome 
laboratory just described another hazard for CD8+ T cell-mediated immunity. They 
showed that human HSV infected cells somehow deliver an off function signal to CD8
+ 
CTL when they come in contact [ 68]. Hence, the CD8+ T cells theoretically should not be 
able to kill the virus infected epithelial cells. Presumably this negative interaction is 
counteracted by other molecules in the milieu, most notably IFN-y. The latter is present 
in high concentration in fever blisters as are a number of other cytokines and chemokines. 
Most notably these include TNF-a., other interferons, and IL-12. These molecules help 
orchestrate the inflammatory response with its arsenal of antiviral defenders. Amongst 
the protective molecules antibody must also be considered since this can neutralize 
extracellular virus even if retarded by the mechanisms described by the Friedman group 
[69]. 
Defense against HSV is usually advocated to largely result from the action of 
cytotoxic CDS+ and CD4+ T cells and the products ofThl CD4+ T cells [61,65]. 
However, formal proof for this opinion is lacking. Mouse studies clearly show that IFN-y 
and perhaps TNF-a. play a major role in antiviral defense [70]. Curiously, IFN-y may be 
directed at infected cells and cause them to purge themselves of viral products. Some 
elegant studies from the Hendrick's lab showed that antigen-specific CDS+ T cells in the 
infected mouse trigeminal ganglion appeared to purge cells of HSV and prevent 
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productive infection [7 1 ]. This process was even advocated as the true means by which 
RSV sustains latency- a hard pill to swallow for the countless souls who have worked on 
molecular mechanisms of HSV latency! 
What the mouse tells us about HSV infection 
Many groups have evaluated the role of the adaptive immune components against 
HSV in the mouse. Such studies, more or less confirm many of the concepts that have 
emerged from human investigations, but some discrepancies do exist. The biggest 
problem with mouse studies is that almost all of them use primary infection models, 
while the main problem in humans is recrudescence. Moreover, virus can readily spread 
to the CNS and cause lethal encephalitis in the mouse. Protection against such 
encephalitis appears to be the primary domain ofC08+ T cell mediated immunity [72]. 
This was shown more than twenty years ago and studies done since that time have merely 
confirmed and extended these initial observations. A problem has always been to explain 
how C08+ T cells act to protect the CNS, since neurons have little or no MHC class I 
molecules and HSV infection is supposed to downregulate whatever they have [73]. . 
However, adoptive transfer experiments comparing the protective efficacy of COS+ T 
cells with other cell types along with observations in models which CDS+ T cell function 
was compromised all point to them as neuroprotectors [74,75]. 
It might be that the neuroprotection proceeds other than by cytotoxicity, certainly 
an unwanted effect on neurons since such cells are not replaced. Thus, as mentioned 
previously, the Hendricks group demonstrated that in the mouse PNS, neuron protection 
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appeared to be mediated by IFN-y secreted from HSV immune cos+ T cells [76]. The 
IFN-y was proposed to purge the neurons of viral products, a concept first described by 
Frank Chisari and colleagues for the protective effects of CDS+ T cells against Hepatitis 
B infected liver cells [77]. 
Control of infection at peripheral sites in the mouse can be accomplished by both 
CD4+ and cos+ T cells as well as by antibody. On a cell to cell basis CD4+ T cells 
appear to be more effective, but this may vary between mouse strains [78]. Moreover, the 
protective effects of both CD4+ and CDS+ T cells appears to depend on the IFN-y 
response [79]. In accord with this, STATl -I- and IFN-y receptor _,_ mice are more 
susceptible to infection, as are IFN-y -l·mice [12,80]. Curiously, the effect of IFN-y may 
act via NO induction, primarily released by IFN-y activated macrophages [50]. 
Another aspect of HSV immunity that the mouse has helped us understand is how 
various aspects of immunity are induced and regulated. Focus has been directed at a 
variety of dendritic cells and their role as APC as mentioned previously. Surprisingly, of 
the large number of DC subtypes, CDS+ lymphoid DC appear to be the most successful at 
inducing T cell immunity [23,24]. Moreover, such DC appear to receive their antigen 
from other cell types by a process termed cross-priming [25] .  Currently, it is not clear if 
cross-priming forms part of a significant immune induction event in humans. 
The other series of events which the mouse has helped elucidate is the influence 
of regulatory cells on immune induction and effector function. Suvas et al recently 
demonstrated that both the magnitude and function of CD4+ and ·ens+ T cell responses 
following either infection or vaccination was hampered by a concomitant regulatory T 
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cell response [81] . Curiously, mice were more protected from HSV challenge if their 
Treg response was abrogated. Subsequent studies also showed that recall vaccination 
responses as well as humoral responses at mucosa! sites were similarly compromised by 
the Treg response [82]. The relevance ofT regulation to HSV pathogenesis in the mouse 
as well as in human systems continues to be investigated. One might wonder why such a 
process exists since it hampers the efficacy of host defense against the virus. The answer 
to this seems to lie in the fact that Tregs also serve a beneficial role and act to minimize 
collateral tissue damage associated with the effector function of T cell mediated 
immunity [83]. Such concepts were recently reviewed [84]. It could be that vaccines that 
fail to activate the Treg response along with effector function might be more efficacious. 
Such issues are under investigation. 
The memory T cell response to HSV: Why is it unable to prevent 
reactivation? 
A major issue for vaccinology is how to maximally induce and retain memory 
responses to pathogens so that re-infection, or in the case ofHSV, reactivation, is kept at 
a sub-clinical level. Recently, a number of fundamental studies have established ground 
rules governing the generation and maintenance of CDS+ T cell memory [85,86]. These 
studies were performed primarily using acute infection models (LCMV) and model 
antigen systems ( ovalbumin). Far less is known about CD4+ T cell memory, although it 
appears that this component is usually reduced in magnitude and less sustained than 
CD8+ T cell memory. Moreover, alteration in the functional subsets ofCD4+ Th memory 
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cells has been observed over time in some chronic viral infections. It appears that Th cells 
lose the ability to produce critical cytokines over the course of the disease, starting with a 
decline in IL-2 and then followed with reduced levels of TNF-a.· Surprisingly, IFN-y 
levels appear to remain constant [87]. 
The focus of memory studies has been on COS+ T cell memory, a component that 
may be most critical for clearance of HSV infection, at least in the natural host. In 
consequence, the application of a fundamental understanding of COS+ T cell memory will 
likely have application to vaccine design, especially the long sought for therapeutic 
vaccines. It is evident that short-term stimulation of naive antigen-specific COS+ T cells 
is sufficient to trigger a program of proliferation and differentiation into effector cells that 
can react directly against antigen expressing cells [88]. These cells are generally both 
cytotoxic and able to generate a range of cytokines critical for antiviral control, especially 
IFN-y. After the peak of the effector response, which occurs at approximately 1 week 
after infection, the vast majority of these effectors die of apoptosis. A small percentage of 
this population, about 5-10%, survive the contraction phase ( days 10-15) and go on to 
form the long-lived memory pool. These cells produce elevated levels of anti-apoptotic 
proteins, such as bcl-2, and express (or re-express), important receptors for survival, such 
as IL-7 receptor [86]. It has been noted that cells which are destined for memory also 
express the homodimeric C08aa molecule on their surface, but the role for this surface 
protein is not clear at present [89]. Some of these cells remain in the lymphoid tissues 
(so-called central memory cells), due to re-expression of CCR7. However, the effector 
memory subset loses CCR 7 on their surface and migrates to peripheral sites, retaining the 
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capacity to make cytokines and kill infected cells upon contact. These effector memory 
cells then patrol the peripheral tissues indefinitely. 
The central memory cells remain more or less static in number over prolonged 
periods, but the small fraction that do die are replaced by a slow turnover of such cells. 
This so-called homeostatic division is not driven by antigen, but is believed to be a 
response to endogenous cytokines such as IL-15 and IL-7 [90]. Antigen re-exposure 
results in a rapid recall of the central memory cells into proliferation and differentiation 
into effector cells. Such cells also tend to move into tissues, the usual site of new antigen 
introduction. The details· of such events are thought to differ depending on the different 
types of infection and perhaps other factors. For instance, in an infection model of LCMV 
Clone 13, which results in a persistent viral infection, functional exhaustion of at least 
some antigen specificities appears to occur. It appears that constant availability of antigen 
tends to prevent the development of a stable central effector memory pool [86]. A similar 
event may exist in HSV infection in the sensory ganglia, but the details of events in the 
memory response to HSV infection have yet to be worked out. 
Curiously, whereas the initial expansion and effector response by cog+ T cells 
appears to occur in response to a variety of antigen preparations and can occur without 
signals from other lymphocytes, the long-term memory response appears to require 
signals from other helper T cells at the time of immune induction [91]. It was shown, for 
example, that when CD4+ helper T cells are absent or not stimulated during the time of 
cos+ induction, a defective long-term memory response ensues [92-94]. In the case of 
murine responses to HSV, we observed that antigen formulations that engage narve COS+ 
specific T cells, but not antigen specific CO4+ T helper cells, resulted in normal acute 
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CDS+ acute responses of the CDS+ T cells, but a poor memory response [95]. In addition 
to the size of the memory pool, the function of these cells was also diminished. Upon 
antigen re-exposure the recalled population demonstrated lower overall avidity in 
comparison to CDS+ T cells that had received help during priming [95]. Currently, the 
actual mechanism by which helper T cells communicate signals resulting in optimal 
memory responses is not fully understood. One idea, however, is that signals from the 
helper T cells influence the maturation status and function of the DC that is presenting 
antigen. Most likely this "signal" is linked to CD40 on the DC binding to CD40L present 
on CD4+ T cells. This interaction, termed licensing by the Matzinger group, results in a 
number of effects on DC, including enhanced costimulatory molecule expression (some 
of which may be critical for memory development) as well as the secretion of key 
cytokines such as IL-12 [96]. 
There seems to be general agreement that helper cell costimulation is generally 
required for optimal memory CDS+ T cell responses, although with some agents the 
pathogens themselves promote a range of nonspecific signals, primarily via the strong 
stimulation of various TLRs that may substitute for helper effects. Less is known about 
the necessity for helper cell stimulation during other phases of the CDS+ T cell response 
profile, such as the contraction, maintenance, and recall phases. Furthermore, it is 
important to understand if in conditions of defective CDS+ T cell memory some form of 
rescue allowing normal function can be achieved. Thus in HSV immunity, it could be that 
those subject to frequent or severe recurrences may have some deficiency in central or 
tissue residing effector memory CDS+ T cells. In mouse systems with a defective CDS+ T 
cell memory response we have achieved some level of rescue in various ways. Toka et al 
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co-administered IL-15 plasmid DNA at the time of priming with plasmid DNA encoding 
gB as well as during the memory phase. This treatment led to enhanced memory pool 
numbers as well as increased functional capacity of the responding CDS+ T cells [97]. 
Efforts might also be directed at increasing IL-7 receptor levels on either effector cells of 
existing memory cells in order to enhance or maintain adequate memory responses. 
It will be important to develop and test vaccines in humans that express IL-15 or 
other such molecules that may serve to "top up" the efficacy of CDS+ T cell memory 
responses against HSV. Other forms of activation may also be successful including 
immunization with persistent cross-reacting vehicles, use of TLR agonists, and possibly 
the use of cytokine activators. 
The immune response to HSV and immunopathology 
Effector T cell recognition of virus infected or viral antigen expressing cells can 
result in target cell destruction, but usually an inflammatory reaction is also elicited that 
causes collateral tissue damage. This outcome, which is usually set off by CD4+ effector 
T cells recognizing their cognate antigens, is mediated in large part by inflammatory 
cytokines [98]. Such inflammatory reactions of varying intensity invariably occur at 
tissue sites of virus infection. Although often painful and tissue damaging, they are a 
small price to pay for control of infection. Moreover, the tissue at most sites is usually 
repaired and thus functions normally. Alas, there are exceptions to this generality. At 
some sites inflammatory reactions can cause profound and often permanent damage to 
function. Sites such as the eye and brain represent examples. With respect to HSV, we 
understand best the consequences of chronic inflammatory reactions in the eye [98,99]. 
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Thus, HSV infection commonly affects the eye, but typically only the epithelium is 
affected. The painful event resolves, especially if treated with antiviral drugs. However, 
in about 20% of cases the corneal stroma becomes involved and a chronic inflammatory 
reaction occurs whose management requires long-term treatment with powerful anti­
inflammatory drugs. This stromal keratitis lesion (SK) is mainly a CD4+ T cell-mediated 
immunopathological response to virus. In support of this, CD4+ T cells with antiviral 
specificity can be recovered from corneal buttons long after primary infection [ 100]. 
Understanding of the details of SK pathogenesis comes mainly from experimental 
infections in niice models. In this model, SK results from primary ocular infection with 
HSV and, as in humans, lesions are immunopathological and orchestrated principally by 
CD4+ T cells [98,101]. Multiple other events are involved that include additional cell 
types, cytokines, chemokines, angiogenic factors, and stress proteins. The pathogenesis 
of SK has been reviewed elsewhere [98,102]. Curiously, the virus which initiates the 
lesion is only briefly present in the eye and then usually not as infectious virions in the 
inflamed stromal tissues. Despite this, the lesion is usually progressive and certainly 
increases in severity for some time after virus has been controlled by the immune 
response. This observation, which parallels what usually occurs in human SK, supports 
the notion that the lesion may be an immunopathogical reaction against viral antigens, but 
subsequently becomes sustained by an autoinflammatory process [ 102]. 
An additional site where HSV sets off an immunopathological reaction is in the 
sensory ganglia where HSV sets up latency. In the mouse, and perhaps in humans too, a 
long-term inflammatory reaction in the sensory ganglia occurs after virus is transmitted 
from peripheral sites of infection [71]. This reaction is dominated by CDS+ T cells, many 
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of which, at least in the C57BL/6 mouse, are viral antigen-specific. Some suggest that 
these CD8+ T cells somehow repress virus in neurons from replicating abundantly, which 
would result in the destruction of these irreplaceable cells [103]. This process, which has 
been called viral purging, may be independent of true HSV latency [71]. This fascinating 
topic was recently reviewed [103]. 
Finally, HSV is an occasional and usually tragic cause of encephalitis. Most 
would consider the human syndrome to largely represent a viral-driven inflammatory 
event with little or no role for immunopathology [57]. However, recent studies in a 
mouse model have indicated that RSV-induced encephalitis may represent largely an 
immunopathogical reaction reminiscent of the situation in the cornea [ 16]. The brain, like 
the eye, cannot sustain long-term immunopathological reactions without compromising 
its function. 
HSV vaccines 
HSV 1 and 2 stand out as tw� of mankind's more prevalent and significant viral 
pathogens that so far have not been satisfactorily controlled by vaccines. It is not for lack 
of trying, and many candidate preparations have been put on the market place. Many, in 
fact, have appeared efficacious when tested by their developer, but none have stood up to 
long term evaluation by disinterested parties. Currently, a vaccine is in the final phases 
of testing and may soon be available in the USA. This GSK vaccine is an adjuvanted 
protein vaccine that upon initial testing by its developers was shown to provide 
significant protection of seropositive women against HSV-2 infection from their 
seropositive partners [64]. The obverse situation provided no such protection. This GSK 
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vaccine appears to be showing protection even though the approach differs little from a 
previous vaccine discarded because of discouraging results. However, the adjuvant being 
used for the apparently successful GSK vaccine ( alum and deacylated monophoshorylipid 
A) is different and may be able to better emphasize the CD4+ type one response pattern 
considered important for protection [ 64]. Another possibility is that the vaccine may be 
conferring some protection to women since it induces a good protective antibody 
response in the genital tract. These issues require investigation as does the reasons for 
the female-only protection. 
We would, from our previous discussions, speculate that vaccines need to that 
additionally induce notable CDS+ T cell responses to be optimally protective. Although 
not formally tested, the GSK vaccine is unlikely to provide epitopes for all MHC types 
and the adjuvant may not represent an ideal one to induce CDS+ T cell responses. The 
induction of optimal HSV specific CDS T cell response will likely to require different 
technology than the GSK vaccine approach. For example, attenuated viral vaccines 
would be more likely to induce CDS+ T cells. Such vaccines have been tested in the past 
and none have been adopted for widespread use. One candidate looked particularly 
appealing at least from an armchair perspective. This was the discontinuous replicating 
vaccine {DISC) that was a glycoprotein H deletion mutant that, except in complementary 
cells, would only undergo a single cycle ofreplication [ 104]. This DISC vaccine did well 
in animal testing and had at least a phase II trial in humans. Its discard by the industry 
probably means it is not sufficiently immunogenic or too complex to develop 
commercially. 
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HSV vaccinologists are left therefore in a state of frustration since currently there 
is no ideal solution on the horizon. It means that more fundamental research on HSV 
immunobiology is required in model systems but more particularly in humans 
themselves. _ We emphasize the latter since animal models tend to be the bearers of good 
news at least when it comes to prophylactic vaccine candidates. Were we rodents, in fact, 
we would already have a pharmacy full of valuable vaccines. Thus killed vaccines, 
attenuated mutants, recombinant vaccines of numerous types, DNA vaccines, adjuvanted 
proteins, and peptides may all provide useful immunity, at least when used 
prophylactically. Alas we are primates, but fortunately with brains and imagination. The 
challenge remains to use our creative skills and overcome the vaccine road block. New 
clues from those optimists who think outside the box are encouraged to take up the 
challenge. 
Conclusions 
Additional work is clearly needed to further understand how HSV accommodates 
itself so well to the perils of both innate and adaptive immunity. We need to devise 
prophylactic vaccines which, even if inadequate to preclude infection, can dampen such 
to subclinical levels. These future vaccines will likely need to take advantage of our ever 
expanding knowledge of adjuvants and the mechanisms by which they shape and enhance 
defenses. We anticipate that successful prophylactic vaccines may be only just over the 
horizon. Therapeutic vaccines, which in the Western :world may provide more rewards to 
the marketplace, could prove more problematic to develop. We shall be challenged to 
improve upon nature's vaccine since the virus itself, forever resident in those subject to 
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recurrent disease, appears unable to confer adequate protective immunity. Modern 
medicine has solved many of mankind's problems. One hopes therapeutic anti-RSV 
vaccines become added to the list. 
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Heat-Shock Protein 70 Acts as an Effective Adjuvant in 
Neonatal Mice and Confers Protection Against Challenge With 
Herpes Simplex Virus 
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Abstract 
Immunization of the neonate is a highly desirable goal for vaccine developers, since the 
neonate is profoundly susceptible to a number of viral and bacterial pathogens. The 
neonatal immune system tends to generate Th2 recall responses, known as neonatal 
tolerance, which may not protect against viral challenge later in life. In this study we 
demonstrate that a potent immune proinflammatory stimulator, heat-shock protein 70 
(hsp70), can act as an effective and safe adjuvant in neonates. Priming of neonates with 
hsp70 coupled to a viral MHC Class I-restricted epitope (gB498-505) and injection with 
recombinant gB generated strong cytotoxic T lymphocyte {CTL) responses and a Thl 
primary T helper cell response during the neonatal period. In addition, enhanced CTL 
and predominant Th 1 recall responses to viral antigens were observed following 
secondary challenge as adults. These responses were sufficient to allow protection against 
a lethal challenge with Herpes Simplex Virus Type-1 (HSV-1 ). Therefore, hsp70 in 
conjunction with viral epitopes and recombinant viral protein can perhaps prime 
protective immune responses to herpes viruses early in life when infection, which can be 
life-threatening, and the establishment oflatency frequently occur. 
Introduction 
Exposure to antigens in utero or shortly after birth usually leads to antigen-specific 
tolerance, but exceptions to this rule do exist and vaccination is possible. Antigenic 
exposure during the neonatal period is believed to lead to the development of Th2 
responses [1,2], rather than Thl responses needed to prevent or control viral infections 
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such as Herpes Simplex Virus-1 (HSV-1) that frequently occur during this time. The 
Matzinger group suggested that the neonatal system, though not fully mature, may be 
able to respond if antigens were presented by adult dendritic cells (DC), suggesting that 
neonatal DC may be handicapped in their ability to prime Th 1 responses [3]. In addition, 
other requirements for an effective response in the neonate are strong stimulation of the 
innate immune response as well as repeated immunizations [4]. Upregulation and 
engagement of costimulatory molecules (CD80, CD86, and CD40) on antigen presenting 
cells, especially dendritic cells (DC), appears to be of extreme importance. In addition, 
due to the maturity level of the immune system it may be more difficult to induce such 
costimulatory molecules on neonatal DC in comparison to adult DC [1]. Curiously, a 
recent report suggests that neonatal DC may be able to upregulate these key 
costimulatory molecules following stimulation as efficiently as adult DC [5]. Production 
of critical proinflammatory mediators, such as IL-12, may also be limited in neonatal DC 
[6]. 
A number of groups have devised strategies to overcome the perceived limitations 
of neonates. Some examples include immunization with antigen emulsified in Complete 
Freund's Adjuvant (CFA) [7], immunization with a low level ofreplicating retrovirus [8], 
use of a herpes virus capable of only one round of replication [9], use of plasmid DNA 
vaccines [10-14], plasmid DNA vaccines in conjunction with genetic adjuvants [15], and 
injection with antigen along with CpG motifs [16,17]. These approaches were all 
successful in generating Thl responses as well as effective cell-mediated immunity, but 
additional novel as well as safe approaches are desirable [18]. Each of the 
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aforementioned strategies possesses possible safety limitations for use in humans for 
vanous reasons. 
HSV-1 or HSV-2 infections of neonates can lead to life-threatening situations 
[ 19]. Therefore, a vaccine that could be administered during this period would be of 
particular value, since the neonatal response may not be able to control viral infection, 
spread, and replication. Such events may ultimately lead to infection of the CNS, 
encephalitis, and possibly death. Typically the neonate does control the infection and the 
virus then most likely retreats into sensory ganglia and sets up latency, setting the stage 
for future recrudescent lesions and painful outbreaks throughout the life of the individual. 
Several investigators, particularly the Srivastrava group, have investigated the use 
of heat-shock proteins (hsps) in the generation of both humoral and cell-mediated 
immunity [20]. Hsps are capable of mediating cross-presentation of antigen (presentation 
of exogenous antigen on MHC Class I) and are able to generate efficient CD8+ T cell 
responses to both tumors and virus infected cells [2 1 ,22] . More importantly, hsps are self­
proteins that possess strong adjuvant properties that lead to the production of 
proinflammatory mediators [23,24]. Binding ofhsps has been shown to induce 
production of IL-1 p, IL-12, IL-6, and TNF-a from antigen presenting cells. In addition, 
hsp binding to the surface of APC leads to the secre�ion of chemokines such as MIP-1 a, 
MIP-l P, and RANTES [25]. Exposure of DC to hsps also induces maturation and 
migration to the draining lymph node [26]. Also, hsp immunization has been 
demonstrated to prevent TNF-associated toxic shock [27]. These characteristics make hsp 
immunization an attractive candidate in the neonate. 
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Recent work from Schoenberger, Chen, and Bevan has demonstrated the 
importance for CD4+ T cell help at the time of priming of CDS+ T cells [28-30]. 
Therefore, it would be likely that CD4+ help would also be critical during the priming of 
CDS+ T cell responses in the neonate for the development of long-term memory. 
In this study we addressed whether priming of neonatal mice with hsp70 coupled 
to the immunodominant peptide epitope from glycoprotein B (gB) (gB49S-505) in 
C57BU6 mice in conjunction with recombinant' gB protein would be able to prevent 
neonatal tolerance, generate protective Thl and CDS+ CTL memory recall responses, and 
lead to the production of gB-specific antibody responses. Such immunized mice were 
then subjected to a lethal zosteriform challenge with HSV-1 to ascertain if protective 
immunity had been established. 
Materials and Methods 
Mice 
Four- to five-week-old C57BL/6 (H-i'} mice were purchased from Harlan Sprague­
Dawley (Indianapolis, IN) and bred in our animal facility to generate neonates. In 
conducting the research described in this work we adhered to the Guide for the Care and 
Use of Laboratory Animals as proposed by the committee on care of Laboratory Animal 
Resources Commission on Life Sciences of the National Research Council. The facilities 
are fully accredited by the American Association for Accreditation of Laboratory Animal 
Care. 
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Peptides 
The HSV gB ( amino acids 498 to 505) peptide SSIEF ARL and the chicken ovalbumin ( aa 
257 to 264) peptide SIINFEKL were synthesized and supplied by Research Genetics 
(Huntsville, AL) 
Viruses 
HSV-1 - 17  was grown on Vero cells (ATCC catalog no. CCL8 1 ), titrated, and stored in 
aliquots at -80°C until use. The recombinant vaccinia virus encoding the minigene 
SSIEFARL (VV-gB) was kindly provided by S. S. Tevethia [3 1 ] .  
Recombinant hsp70 protein preparation 
The murine hsp70 gene was amplified using high-fidelity PCR from the hsp70. J gene 
from a plasmid kindly provided by S .  Calderwood [32] . It was then inserted into the pET-
22b + expression vector (lnvitrogen, Carlsbad, CA) using an engineered 5 '  NdeI site and a 
3 '  BamHI site. The insert was then sequenced for confirmation. Recombinant protein was 
then produced in transformed BL2 1 (DE3) E. coli (Invitrogen) and purified as previously 
described [33] .  In brief, the bacteria were lysed using a french press following a 4 h IPTG 
induction and then dialyzed in binding buffer. The dialyzed lysate was then purified using 
ATP-agarose affinity chromatography, dialyzed in binding buffer, and then further 
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purified by ion exchange chromatography to remove any contaminating DnaK. (Q 
sepharose was used rather than POROS HQ). The final elute was then dialyzed in PBS. 
Western blot analysis demonstrated a single band at approximately 70 kD. Limulus 
amebocyte lysate testing (Bio Whittaker, Walkersville, MD) revealed that the final protein 
product contained only trace levels of endotoxin (3 EU/ml). 
Cell lines 
Vero (African green monkey kidney cell line) was used for growing of viral stocks and 
MC38 was used as a target cell (C57BL/6, H-i'}. All cell lines were cultured in 
Dulbecco's Modification ofEagle's medium (Mediatech, VA) supplemented with 10% 
heat-inactivated fetal bovine serum, 5 mg/L of gentamicin sulfate, and 2 mM L­
glutamine. T cell stimulation assays were carried out in 25 mM Hepes buffered RPMI-
1640 media (Sigma, ST. Louis, MO) containing 10% heat-inactivated fetal bovine serum, 
5 mg/L of gentamicin sulfate, 0.05 mM 2-ME, and 2 mM L-glutamine. 
Hsp70 and peptide binding 
SSIEF ARL and SIINFEKL peptides were loaded onto hsp70 according to a previously 
described procedure [21]. Briefly, peptides were incubated with hsp70 in binding buffer 
(phosphate-buffered saline with 2 mM MgCh) at 37°C for 60 min (5 µg each in 50 µ1 
total vol, 75:1 molar ratio). ADP was then added to 0.5 mM (Sigma) and the incubation 
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was continued for another 60 min. Preparations were then added to 50 µ1 of Alhydrogel 
aluminum hydroxide (Superfos Biosector, Denmark) and incubated at 4°C for 2 h. 
Neonatal immunizations 
Neonatal C57BL/6 mice were immunized i.p. on day 7 after birth with either 5 µg of 
SSIEF ARL or SIINFEKL coupled to 5 µg of hsp70 in binding buffer with alum added in 
a 1 :  1 ratio for a total vol of 1 00 µ1/ mouse. Some groups received 10  µg/mouse 
recombinant full-length gB protein (<5 EU LPS/ml) (a kind gift from Chiron, Emeryville, 
CA) in their immunization either in conjunction with hsp70 and peptide or alone. 
Neonatal spleen responses were then assessed 7 d post immunization or additional 
immunized mice were allowed to mature to 7 weeks old and challenged i.p. with 106 pfu 
VV-gB. T cell responses in the spleen were then analyzed 5 days later. 
CTL assay 
The CTL assay was performed as described earlier [34]. Briefly, effector cells generated 
after a 5 d in vitro expansion (with SSIEFARL-loaded, irradiated splenocytes) were 
analyzed for their ability to kill major histocompatibilitycomplex (MHC)-matched 
antigen-presenting targets. The cells were mixed with the target at various ratios and 
incubated for 4 h. The targets included 5 1Cr-pulsed MHC-matched SSIEFARL-pulsed as 
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well as control SIINFEKL-pulsed MC38 target cells. Percent specific lysis was then 
calculated according to the following formula: 
100 x [(experimental release - spontaneous release)/ (maximum release - spontaneous 
release)]. 
Intracellular IFN-y staining 
To enumerate the number ofIFN-y producing cells intracellular cytokine staining was 
performed as previously described [35]. In brief, 106 freshly explanted splenocytes were 
cultured in U-bottom 96-well plates. Cells were either left untreated or stimulated with 
SSIEF ARL peptide (1 µg/ml) for 6 h at 37°C in 5% CO2• Brefeldin A was added for the 
duration of the culture period to facilitate intracellular cytokine accumulation. Cell 
surface staining was then performed followed by intracellular cytokine staining using the 
Cytofix/Cytoperm kit (BD Pharmingen, San Diego, CA) in accordance with the 
manufacturer's recommendations. For intracellular cytokine staining the antibodies used 
were FITC-anti-CD8a and PE-anti-lFN-y (clone XMGl.2). All antibodies were 
purchased from BD Pharmingen and samples were collected on a BD F ACScan and 
analyzed using CellQuest software. 
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ELISPOT and ELISA 
ELISPOT assay for IFN-y secreting cells was performed as previously described [35], 
except for slight modifications. Briefly, 96-well filter plates (Millipore HA) were coated 
with capture antibody for IFN-y (RA-6A2)(BD Phanningen) ON @ 4°C (BD 
Phanningen) (2 µg/ml) in PBS. Plates were then washed with sterile PBS and blocked 
with culture media containing 10% FCS. Splenocytes from a single cell suspension were 
incubated at various effector:stimulator ratios. 105 irradiated, SIINFEKL or SSIEFARL­
pulsed irradiated (3000 rads), syngeneic splenocytes were used as stimulators. Serial 2-
fold dilutions of effectors were then incubated with stimulators starting with 5 x 105 and 
ending with 6.25 x 104 • 20 U/well of IL-2 was also added to the culture. Cells were then 
incubated for 48 h at 37°C, 5% CO2 • Wells were then washed with PBS, followed by 
PBS-Tween. Biotin anti-mouse IFN-y (XMG 1.2) (BD Phanningen) (1 µg/ml in PBS 3% 
BSA) was then added to each well and incubated ON @ 4°C. Wells were then washed 
with PBS-Tween and streptavidin-conjugated peroxidase (Jackson Laboratories) in PBS 
3% BSA was added to each well (1 µg/ml) for 30 min @ 37°C. Wells were then washed 
with PBS-Tween and developed using 3-amino-9-ethylcarbazole (AEC) (Sigma) in 0.1 M 
acetate buffer pH 5.0, containing 0.05% H202 • Reactions were allowed to proceed for 10 
min and were ended by extensive washing with dH20. Plates were allowed to dry and 
then counted on a stereo microscope. 
ELISA was performed as previously described [36] to determine cytokine levels 
(IFN-y and IL-4) in supematants of stimulated CD8+ and CD4+ T cell cultures stimulated 
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with peptide or rgB protein. Antibody pairs and concentrations were identical to those 
used for ELISPOT. The substrate ABTS was used for development. Determination of gB­
specific total lgG, IgG2a, and lgG 1 antibody in the serum was performed with 
appropriate HRP-goat-anti-mouse detection antibodies (Southern Biotechnology 
Associates, Inc., Birmingham, AL). Briefly, plates were coated with rgB (1 µg/ml in 
PBS) and various dilutions of serum were incubated ON @ 4°C. The appropriate HRP­
conjugated goat anti-mouse detection antibody (1 µg/ml) was then used for detection and 
the plates were developed with ABTS as previously stated. 
Virus challenge 
A zosteriform challenge experiment was performed as previously described [3 7] .In 
brief, the left flank area was depilated prior to challenge by a combination of hair clipping 
and use of the depilatory chemical (Nair; Carter-Wallace, Inc., New York, NY). The 
animals were anesthetized with Metofane (Pitman-Moore, Inc., Mundelein, IL), and 20 
scarifications were made in a -4-mm2 area. To such scarifications 10 µl containing 2 
X 1 05 PFU of HSV- 1 (strain 17) was added and the area was gently massaged. Animals 
were inspected daily for the development ofzosteriform ipsilateral lesions, general 
behavior changes, encephalitis, and mortality. The· severity of the lesions were scored as 
follows: 1 +, vesicle formation; 2+, local erosion and ulceration of the local lesion; 3+, 
mild to moderate ulceration with spreading of lesion; 4+, severe ulceration, hind limb 
paralysis, and encephalitis; and 5, death (mice that were moribund and hence euthanized). 
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Statistical analysis 
The data were analyzed by using a 2-tailed student's t test, and p values less than .05 
were deemed significant. 
Results 
Hsp70 immunization regimens induce strong CDS+ T cell responses during the 
neonatal period 
We first set out to determine ifhsp70 + peptide immunization strategies, which have 
previously been demonstrated to be an effective strategy in adult mice [38], would 
generate efficient CD8+ cytokine and CTL responses in neonates. Preliminary 
experiments in our lab showed that hsp70+SSIEF ARL immunization of neonates without 
alum enhanced adult recall responses to HSV-1 and conferred protection from a lethal 
zosteriform challenge with HSV-1 - 17  at 7 weeks of age ( data not shown). Developmental 
studies of mice suggest that 7 days after birth most accurately correlates to the immune 
maturity level of a newborn human [39] . Therefore, 7 day old mice were used in this 
study and given an intraperitoneal (i.p .) injection ofrecombinant murine hsp70 (5 µg) 
non-covalently complexed to gB498-505 (SSIEF ARL) (5 µg) and adsorbed to alum (1 : 1 
ratio, 1 00 µl total) prior to injection. Additional groups also received recombinant gB 
protein (10 µg) in addition to hsp70 and peptide. Control groups were injected with either 
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hsp70 and an irrelevant .peptide (OVA 257-264 or SIINFEKL) in alum, hsp70 + 
SIINFEKL + recombinant gB in alum, SSIEF ARL alone in alum, SSIEF ARL + gB in 
alum, or gB in alum alone. Neonatal mice were then assessed 7 days later for CTL and 
cytokine responses in the spleen. As seen in figure IA (see appendix), mice that received 
hsp70, SSIEF ARL, and gB generated significantly higher levels of IFN-y producing cells 
against both MHC Class I and Class II-restricted epitopes. Mice that received hsp70, 
SIINFEKL, and rgB demonstrated a modest response, while all other groups failed to 
generate detectable responses. Following a 5 day in vitro expansion with irradiated 
syngeneic APC loaded with gB498-505, stimulated cultures were tested for their ability 
to lyse Cr5 1 �labelled, peptide-pulsed target cells (MC38). Neonatal derived CTL 
demonstrated the capacity to kill gB498-505 loaded target cells, provided that the neonate 
had been primed with hsp70 and gB498-505 (Figure lB). Neonates that received hsp70, 
gB498-505, and rgB mounted the most effective primary CTL responses, leading to 
greater than 50% lysis (Figure lB). Mice receiving hsp70 and SSIEF ARL also mounted 
significant cytotoxic responses, albeit slightly less than groups which received hsp70, 
SSIEFARL, and rgB. The group that received hsp70, SIINKEKL, and rgB consistently 
produced low levels of CTL, suggesting that gB may possess some immunogenic 
potential of its own. Groups that received SSIEF ARL only, or SSIEF ARL and rgB failed 
to produce any detectable ELISPOT or CTL activity ( data not shown). 
Neonatal hsp70 immunization approaches enhance adult recall responses to antigen 
In order to evaluate the relative numbers of responding memory CDS+ T cells specific for 
gB 498-505 following i.p challenge with VV-gB, both ELISPOT (Figure 2A) and 
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intracellular staining for IFN-y (Figure 2B) were carried out. For recall cytokine response 
evaluation adult mice were immunized as neonates with various regimens, infected with 
VV-gB, and five days later the spleens were removed and stimulated for 48 hours with 
irradiated syngeneic splenocytes loaded with gB498-505 . Mice that received hsp70 in 
conjunction with gB498-505 and rgB produced a statistically significant (p<0.05) (75% 
greater) recall response in comparison to control mice receiving only hsp70 and 
OV A257-264. Mice receiving hsp70 and gB498-505 as neonates also showed enhanced 
responses in comparison to the control mice that received hsp70 and the irrelevant 
peptide (50% greater). However, these differences were not significant, since the primary 
response to VV-gB is extremely strong in C57BL/6 mice and may overshadow small 
differences. Intracellular staining for IFN-y was also performed on adult mice from the 
same set of groups. Again, the most significant elevation in response in comparison to the 
negative control group was found in the group that had received hsp70, gB498-505, and 
rgB (-6-fold). Approximately a 4-fold increase was observed in the group which received 
hsp70 and gB498-505 only. This again supports the need for concurrent CD4+ T cell 
priming during CD8+ T cell priming for optimal memory responses. Cytotoxi_city assays 
(Figure 2C) supported data from ELISPOT and intracellular staining experiments, with 
the group receiving hsp70, SSIEFARL, and gB yielding the highest level ofkilling. It 
was interesting to note the enhanced recall CTL killing in all groups that had received 
rgB as neonates, again suggesting that rgB may have inherent immunogenic properties. 
Groups that received both SSIEF ARL and rgB generated similar responses to mice 
receiving rgB alone in all assays, while control groups that received SSIEF ARL alone 
failed to show any enhanced recall response ( data not shown). 
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CD4+ T cell recall responses from mice immunized as neonates with hsp70-based 
preparations are biased towards Thl 
Since CD4+ T cell responses are critical for controlling HSV-1 infections, we assayed the 
recall response to determine if tolerance was occurring to the rgB administered to the 
neonates. Development of a Thi response is therefore a necessary goal to prevent or 
control HSV-1 infection. Adult recall CD4+ T cell responses were accordingly measured 
in mice that had been immunized as �eonates with various hsp70 regimens and then 
challenged as adults with VV-gB (Figure 3). Briefly, supernatant from splenocytes that 
had been stimulated for 48 h with either gB498-505 (Figure 3A) (for CDS+ T cell 
response) or rgB (for CD4+ T cell response) was examined by ELISA for the presence of 
IFN-y or IL-4 (Figure 3B). Groups receiving a combination of hsp70 and rgB, regardless 
of the peptide conjugated to hsp70, produced strong Thi recall responses to gB. Each 
group produced approximately 3 ng/ml of IFN-y, but secreted only I ng/ml or less of IL-
4. In contrast, groups that did not receive rgB failed to generate large amounts of either 
IFN-y or IL-4. As expected, groups that received rgB without hsp70 to act as a strong 
adjuvant primarily demonstrated a Th2 recall response dominated by IL-4, as expected 
with alum (Figure 3B). 
Neonatal immunization approaches with hsp70 and rgB yield IgG 1 gB-specific 
antibody responses 
Antibody is also a critical factor in limiting or preventing initial infection with HSV-1, 
especially at the site of infection (typically the mucosa). Therefore, we analyzed sera 
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from adult mice that had been immunized as neonates with the various hsp70/antigen 
combinations and challenged with W-gB five days prior to collection (Figure 4). 
Surprisingly, only lgG 1 gB-specific antibody responses were observed, despite the 
development of Thl CD4+ T cell responses. It appeared that inclusion ofhsp70 yielded 
slightly enhanced levels of gB-specific antibody when one compares groups which 
received gB alone versus those that received hsp70 and rgB. However, these differences 
were not statistically significant. Therefore, it is interesting to speculate that neonates 
may have a profound bias to the generation of IgG 1 responses. 
Neonatal vaccination strategies utilizing hsp70 decrease HSV-1 associated lesions 
and prevent mortality 
In an effort to assess the protective capacity of a neonatal hsp70 based vaccine design, the 
zosteriform challenge model was utilized. Briefly, the mice were shaved on the left flank 
and the skin was scratched with a needle. HSV-1 - 17  was then applied to the skin and the 
mice were observed daily for signs of infection and disease progression as described 
earlier. As seen in figure 5A, mice that received hsp70, gB498-505, and rgB faired most 
favorably, developing either no or only minimal signs of infection. Mice that received 
hsp70 and gB498-505 were resistant to death and disease progression (Figure 5B), but 
were not protected from initial infection. In stark contrast, control mice that received 
hsp70 and OV A257-264 developed severe HSV-1 lesions and encephalitis, with 
approximately 75% succumbing to the infection. Mice that received hsp70, OV A257-
264, and rgB also were able to resist infection, comparable to groups that received 
gB498-505 along with hsp70 and rgB. In addition, rgB alone resulted in enhanced 
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immunity to zosteriform challenge, with mice following a similar course of disease to 
that of other partially protected groups. Therefore, it appears that CDS+ T cell immunity 
is important for preventing the spread of the infection, but CD4+ T cell responses and 
specific antibody may play an even greater role in controlling the initial infection [37]. 
Any effective neonatal vaccination strategy would most likely involve such a 
combinatorial approach. 
Discussion 
This study demonstrated that immunization of neonates with hsp70 and the 
immunodominant peptide MHC Class I-restricted epitope from gB along with 
recombinant gB in alum elicited detectable CTL responses during the neonatal period as 
well as strong CTL and Th 1 memory recall responses during adult life. Most importantly, 
CD4+ T cell memory responses in groups that had received hsp70 and gB protein showed 
a clear shift to Thl, demonstrating that neonatal tolerance was indeed averted. In contrast, 
either mixed or strong Th2 responses {IL-4 gB-specific production) were present in 
groups immunized as neonates with rgB in alum without hsp70. Although enhanced 
primary as well as memory CTL responses were noted (by intracellular staining, 
ELISPOT, and CTL analysis) following hsp70 immunization strategies, gB-specific 
antibody responses were not of the expected isotype. Strong gB-specific antibody 
responses were noted in sera of immunized mice at 6 weeks of age, but these responses 
were primarily IgGl in makeup, not IgG2a, as would be expected to accompany a Thl 
response. This observation may be attributed to the relative immaturity of the B cell at the 
time of priming, and similar outcomes have been observed in prior studies by others [ 40]. 
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More importantly, we demonstrated that neonatal immunization with hsp70 based 
approaches can protect mice from subsequent challenge as adults with a lethal dose of 
HSV-1 ( as demonstrated by the zosteriform challenge experiments). Protection is likely 
mediated by a combination of CO4+ T cells, cog+ T cells, and antibody to gB. However, 
when mice were immunized with hsp70 and peptide, only partial protection was noted. 
Most of these mice showed signs of infection but managed to contain the spread of the 
virus and recover completely. These results are in accord with prior studies indicating 
that CO4+ T cells are critical for effective cog+ T cell memory responses against HSV-1 
infection [38]. 
It is striking that inclusion of CO4+ T cell help is critical for both primary 
neonatal responses as well as secondary adult recall responses. It was previously 
demonstrated by Shen [29], Bevan [30], and Schoenberger [28]that CO4+ T cell help is 
critical for memory development of cog+ T cell responses, but primary responses 
appeared to not be affected by the absence of help. It may be plausible that neonatal CTL 
responses are even more reliant upon strong CO4+ T cell help (most likely a key source 
of IL-2 and CD40/CD 154 interaction on DC) for initiation due to their lower precursor 
frequency than in adults. 
Newborns are at high risk of exposure to a number of viral and bacterial 
pathogens, including HSV-1. Nevertheless, most immunizations are not performed until 
2-3 months after birth in humans, since the neonatal immune system preferentially 
mounts Th2 responses following antigenic challenge. This defect in the neonate has been 
attributed to both inadequate presentation (both nature and quality) by neonatal APC, as 
well as insufficient numbers. We have chosen to use the age of 1 week after birth for 
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these studies, since this time has been suggested by others to most closely match the 
maturity level of a newborn human. Successes have been noted in immunization of 
neonatal mice with a number of agents, including plasmid DNA alone as well as CpG 
oligonucleotides in combination with plasmid DNA or proteins. Unfortunately, responses 
in neonates may be weaker than what is observed in adult mouse models for plasmid 
DNA immunizations [14]. In addition, Th responses in plasmid DNA immunizations may 
not be fully directed to Thl recall responses without additional factors such as IL-12 [15]. 
Furthermore, CpG immunizations may be toxic to neonates, as enhanced morbidity and 
mortality has been noted in neonatal immunizations [ 41]. Other successes in the neonate 
include the use of recombinant HSV-1 DISC, which is capable of replication only once 
[9], as well as a low pfu of retrovirus (1 pfu) for infection [8]. Success has also been 
observed using mucosa! immunization with attenuated recombinant adenoviral vectors. 
However, safety concerns and the possibility of a reversion to wild-type virus are always 
a concern when using live virus in a highly susceptible neonate. Other prior approaches 
include CF A as an adjuvant to prevent neonatal tolerance, but drawbacks of this approach 
exist as well, since CFA use can lead to oil induced arthritis [42]. In addition, CFA is not 
approved for use in humans. However, alum is approved for use in humans, and we have 
exploited its ability to create an antigen depot in these studies. Hsp70 also appears to be a 
safe adjuvant in mice, since excess amounts do not lead to TNF-a-mediated shock in 
adult mice [27]. Therefore, use of a protein based adjuvant in alum, such as hsp70, 
appears ideal for safe, effective stimulation of the neonatal immune system. It was 
interesting to note that all groups that received rgB demonstrated enhanced CD8+ T cell 
responses. This observation could be attributed to possible adjuvant effects exerted by the 
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glycoprotein itself, which could conceivably activate a toll-like receptor {TLR). Viral 
glycoprotein activation ofTLR2 has been observed by the Compton group [43] .  
Infection of the neonate with HSV- 1 can even lead to life-threatening situations, 
most likely due to the inability of the neonate to mount robust CD4+ and CD8+ T cell 
responses in a timely manner to contain HSV- 1 [ 1 9] .  Neonatal exposure and infection are 
also quite common in HSV- 1 ,  allowing the virus to set up latency· and establish a life­
long infection. Therefore, early intervention is necessary to break the chain of events and 
prevent initial infection. Neonatal immunization approaches utilizing the unique adjuvant 
and cross-priming characteristics ofhsp70 may prove therapeutically useful in allowing 
the neonate to mount a protective response at this vulnerable, early point in life. In 
addition, these early responses should not prove detrimental upon pathogen encounter, as 
one might have expected if Th2 recall responses had been observed. 
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Figure 1 .  Neonatal vaccination generates enhanced primary responses in the 
neonate. 1 days post immunization the spleens were removed and ELISPOT for 
IFN-y production against gB498-505 (filled bars) or rgB (open bars) was 
performed (A) or cells were stimulated in vitro for 5 days and a standard 51Cr 
release assay was performed (B). *p<O. 05 
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Figure 2. Neonatal vaccination with hsp70 regi.mens leads to enhanced memory recall 
responses. Mice that had been immunized 7 days after birth were allowed to mature to 7 
weeks of age. They were then challenged i.p. with VV-gB and the resulting cytokine and 
CTL responses were then measured. IFN-y secreting cells were quantified by ELISPOT 
(A) and intracellular staining for IFN-y (B). A standard 51Cr release assay was used to 
detennine CTL activity (C). *p<0.05 
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Figure 3. Mice receiving hsp70 and antigen generate Thi dominated recall 
responses. Spleen cells from recall response mice were incubated with either 5 
µg/ml gB498-505 (A) or 20 µg/ml rgB (B) for 48 h. The supernatant was then 
tested for either IFN-y (filled bars) or IL-4 (open bars) by ELISA. 
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Figure 4. Despite a predominant Thi recall response, mice immunized as 
neonates mount an lgG 1 gB-specific response following challenge with VV-gB 
during adulthood. Responses from various serum dilutions taken 5 d p.i. with 
VV-gB were measured by ELISA using gB coated plates (1  µg/ml) followed by 
incubation with the appropriate HRP-goat anti-mouse detection antibody. IgGl­
specific responses are depicted as filled bars while IgG2a-specific responses are 
designated as open bars. 
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Figure 5. Mice that received hsp70 and gB antigen display enhanced resistance to 
zosteriform challenge as well as reduced mortality. A zosteriform challenge with 
HSV-1 strain 1 7  was carried out by shaving the left dorsal flank and sraping the 
skin with a 27G needle prior to exposure with HSV-1 .  Mice were graded daily for 
signs of disease (A). Scoring was as follows: 1) local inflammation, 2) defined 
local lesion, 3) spreading of local lesion up the flank, 4) paralysis of hind limbs 
due to encephalitis, and 5) death. Survival rate was also recorded (B). Each group 
consisted of 8 mice and the results are representative of 2 independent 
experiments. 
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Part III. 
An Intranasal Heat Shock Protein Based Vaccination Strategy 
Confers Protection Against Mu cos al Challenge with Herpes 
Simplex Virus 
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Abstract 
Herpes simplex virus (HSV-1) represents a significant obstacle for vaccine designers, 
despite decades of investigation. The virus primarily infects the host at vulnerable 
mucosa! surfaces that progresses to lesion development, latency in nervous tissue, and 
possible reactivation. Therefore, protection at the site of infection is crucial. Mucosa! 
adjuvants are critical for the development of an effective vaccine approach, and heat­
shock protein 70 (Hsp70) represents an attractive candidate for this purpose. This study 
demonstrates that Hsp70 coupled to gB498-505 from HSV-1 induced mucosa! and 
systemic priming of CD8+ T cells capable of protecting C57BL/6 mice against a lethal 
vaginal challenge. Elevated gB-specific cytotoxicity was observed in the spleen of 
Hsp70+peptide immunized mice. In addition, both vaginal IFN-y levels and viral 
clearance were enhanced in mice mucosally immunized with Hsp70 and gB peptide 
versus peptide only control mice or mice receiving Hsp70 and a control peptide. These 
studies demonstrate that Hsp70 can be used as an effective mucosa! adjuvant capable of 
generating a protective cell-mediated immune response against HSV-1. 
Introduction 
Despite decades of research and development, effective vaccines against a 
number of viral pathogens, such as HN and a number of human herpesviruses, are still 
lacking. It appe�s that T cell immunity, including both CD4+ and CDS+ T cells, are 
crucial for controlling and eliminating these chronic viral infections. Despite decades of . 
attempts, no effective vaccine strategy has proved effective against herpes simplex virus 
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(RSV) in human trials. Therefore, additional, novel approaches are necessary and warrant 
investigation. A number of vaccine approaches, both systemic and mucosa!, have been 
investigated against HSV [1]. Some examples include DNA vaccines along with various 
cytokine and chemokine adjuvants [2-5], CpG oligonucleotide motifs along with peptide 
[6,7], heat-shock protein/peptide complexes [8,9], recombinant vaccinia virus expressing 
HSV glycoproteins [1 0], and many others. Moreover, it appears that heat shock protein 
70 (hsp70) coupled to viral peptides may prove useful as vaccine candidates for HSV. 
Hsp70 has been demonstrated to induce the maturation and migration of dendritic cells 
(DC) [ 11 ], leading to the upregulation of costimulatory molecules and the secretion of 
strong proinflammatory cytokines as well as Th 1 associated chemokines [ 12-14]. Recent 
studies from our group demonstrated that when hsp70 was coupled to gB498-505, the 
dominant CDS+ T cell epitope in C57BU6 mice against HSV-1, it induced potent acute 
responses marked by enhanced levels of IFN-y secreting cells and strong cytotoxic T cell 
(CTL) activity. Unfortunately, these responses were not durable, as mice challenged in 
the memory phase gradually lost resistance to viral challenge in comparison to groups 
that were immunized with UV-inactivated HSV-1 or a recombinant vaccinia virus 
encoding gB498-505 as a minigene [8]. This decrease was attributable to the lack of 
CD4+ T cell help during the priming phase. Therefore, additional studies including 
cognate CD4+ T cell help increased long-term effectiveness and memory responses [9]. 
HSV is primarily transmitted via mucosal surfaces, such as the oral and genital 
mucosae. Therefore, efficient immune responses are critical for protection at these 
vulnerable sites and development of vaccine approaches to enhance mucosa! immunity 
against HSV is a major goal [15,16]. The respiratory tract is an attractive route of 
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administration to induce protective immune responses to mucosa! pathogens, especial 
since immune cells primed at the primary mucosa! site appear to migrate to distal 
mucosa! sites, such as the vaginal mucosa. This process has been referred to as the 
common mucosal concept [17]. Several effective mucosa! adjuvants have been tested in 
HSV vaccine trials, and one of the more potent of these in clinical trials in humans was 3-
O-deacylated monophosphoryl lipid A given along with recombinant HSV-2 
glycoprotein D in aluminum hydroxide [ 18]. Unfortunately, the vaccine was only 
effective in women seronegative for both HSV-1 and HSV-2. Other bacterial toxins, such 
as cholera toxin and E. coli enterotoxin, are strong mucosal adjuvants, but significant side 
effects prevent their practical use in humans [19]. Another possible mucosal adjuvant, 
CpG motifs, has also been investigated in mucosal HSV vaccine studies by the Rosenthal 
group [7]. Mucosa! CpG administration along with recombinant protein from HSV was 
an effective approach, generating high levels of CD4+ and CD8+ T cell responses as well 
as RSV-specific antibody responses. Even CpG alone was surprisingly effective at 
preventing vaginal HSV infection for a short period, presumably because of enhanced 
stimulation of innate immunity. In this study we evaluate the potential use ofhsp70 as a 
mucosal adjuvant. Mice were given hsp70 bound to gB 498-505 intranasally (i.n.) or 
intraperitoneally (i.p.) and the resulting systemic CTL response was measured. 
Resistance to vaginal challenge with HSV-1, vaginal cytokine production, and clearance 
of virus was also examined. Our results show systemic responses to gB498-505, 
increased vaginal IFN-y levels, enhanced viral clearance rates, and resistance to vaginal 
challenge. 
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Materials and Methods 
Mice 
Four- to five-week-old C57BL/6 (H-i'} mice were purchased from Harlan Sprague­
Dawley (Indianapolis, IN). In conducting the research described in this work we adhered 
to the Guide for the Care and Use of Laboratory Animals as proposed by the committee 
on care of Laboratory Animal Resources Commission on Life Sciences of the National 
Research Council. The facilities are fully accredited by the American Association for 
Accreditation of Laboratory Animal Care. 
Peptides 
The HSV gB ( amino acids 498 to 505) peptide SSIEF ARL and the chicken ovalbumin ( aa 
257 to 264) peptide SIINFEKL were synthesized and supplied by Research Genetics 
(Huntsville, AL) 
Viruses 
HSV-1 McKrae strain was grown on Vero cells (ATCC catalog no. CCL81 ), titrated, and 
stored in aliquots at -80°C until use. Viral titrations were performed on Vero cell 
monolayers and PFU/ml was calculated. 
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Recombinant hsp70 protein preparation 
The murine hsp70 gene was amplified using high-fidelity PCR from the hsp70. 1 gene 
from a plasmid kindly provided by S. Calderwood [20]. It was then inserted into the pET-
22b + expression vector (lnvitrogen, Carlsbad, CA) using an engineered 5 '  NdeI site and a 
3 '  BamHI site. The insert was then sequenced for confirmation. Recombinant protein was 
then produced in transformed BL21 (DE3) E. coli (lnvitrogen) and purified as previously 
described [21]. In brief, the bacteria were lysed using a french press following a 4 h IPTG 
induction and then dialyzed in binding buffer. The dialyzed lysate was then purified using 
ATP-agarose affinity chromatography, dialyzed in binding buffer, and then further 
purified by ion exchange chromatography to remove any contaminating DnaK (Q 
sepharose was used rather than POROS HQ). The final elute was then dialyzed in PBS. 
Western blot analysis demonstrated a single band at approximately 70 kD. Limulus 
amebocyte lysate testing (Bio Whittaker, Walkersville, MD) revealed that the final protein 
product contained only trace levels of endotoxin (3 EU/ml). 
Cell lines 
Vero (African green monkey kidney cell line) was used for growing of viral stocks and 
MC38 was used as a target cell (C57BL/6 adenocarcinoma, H-i'}. All cell lines were 
cultured in Dulbecco's Modification ofEagle's medium (Mediatech, VA) supplemented 
with 10% heat-inactivated fetal bovine serum, 5 mg/L of gentamicin sulfate, and 2 mM L­
glutamine. T cell stimulation assays were carried out in 25 mM Hepes buffered RPMI-
79 
1 640 media (Sigma, ST. Louis, MO) containing 10% heat-inactivated fetal bovine serum, 
5 mg/L of gentamicin sulfate, 0.05 mM 2-ME, and 2 mM L-glutamine. 
Hsp70 and peptide binding 
SSIEFARL and SIINFEKL peptides were loaded onto hsp70 according to a previously 
described procedure [22]. Briefly, peptides were incubated with hsp70 in binding buffer 
(phosphate-buffered saline with 2 mM MgCli) at 37°C for 60 min (10 µg each in 50 µ1 
total vol, 75 : 1 molar ratio). ADP was then added to 0.5 mM (Sigma) and the incubation 
was continued for another 60 min. 
Immunizations 
C57BL/6 mice were immunized either i.n. or i.p . with either 10 µg of SSIEFARL or 
SIINFEKL coupled to 1 0  µg ofhsp70 in binding buffer for a total vol of 20 µI (i.n.) or 
100 µI (i.p. ). Some groups received only peptide. Immunizations were performed on d0, 
d7 and d21 .  Spleen responses were then assessed 5 d after the 3rd immunization. 
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CTL assay 
The CTL assay was performed as described earlier [ 6]. Briefly, effector cells generated 
after a 5 d in vitro expansion (with SSIEFARL-loaded, irradiated splenocytes) were 
analyzed for their ability to kill major histocompatibility complex (MHC)-matched 
antigen-presenting targets. The cells were mixed with the target at various ratios and 
incubated for 4 h. The targets included 51Cr-pulsed MHC-matched SSIEF ARL-pulsed as 
well as control SIINFEKL-pulsed MC38 target cells. Percent specific lysis was then 
calculated according to the following formula: 
100 x [ ( experimental release -.spontaneous release)/ (maximum release - spontaneous 
release)]. 
ELISA 
ELISA was performed as previously described to determine cytokine levels (IFN-y) in 
vaginal washings [ 6]. Briefly, 96-well EIA/RIA plates were coated with capture antibody 
for IFN-y (RA-6A2)(BD Pharmingen) ON @ 4°C (2 µg/ml) in 1 M Na2HP04• The wells 
were then washed with PBS-Tween and vaginal washings taken every 24 h with PBS 
were incubated ON @ 4°C. For detection wells were washed with PBS-Tween and biotin 
anti-mouse IFN-y (XMG 1.2) (BD Pharmingen) (1 µg/ml in PBS 3% BSA) was then 
added to each well and incubated for lh @ RT. Wells were then washed with PBS­
Tween and streptavidin-conjugated peroxidase (Jackson Laboratories, ME) in PBS 3% 
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BSA was added to each well (1 µg/ml) for 30 min @ RT. Plates were then washed and 
developed using ABTS (Sigma). ELISA readings were taken on an automated ELISA 
reader (SpectraMAX 340, Molecular Devices, Sunnyvale, CA). 
Virus challenge 
Since mice are irregularly susceptible to genital infection with HSV-1 unless they are 
synchronized into di estrous, mice were injected subcutaneously with 2 mg of Depo­
Provera (medroxyprogesterone) (Pharmacia and Upjohn, Kalamazoo, MI) to synchronize 
the ovarian cycle [23]. Five days later each mouse was anesthetized with avertin and 
infected intravaginally with 106 PFU of HSV-1 McKrae strain. Every 24 h a genital 
lavage specimen (washing with 200 µ1 PBS) was collected for viral titration and cytokine 
analysis. Mice were monitored daily for clinical disease and pathology and graded 
according to the following: 0, no apparent infection; 1 ,  mild inflammation of the external 
genitalia; 2, redness and swelling of external genitals; 3, severe redness, inflammation, 
and genital ulceration with loss of hair; 4, hind limb paralysis; 5, death. 
Statistical analysis 
The data were analyzed by using a 2-tailed student's t test, and p values less than .05 
were deemed significant. 
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Results 
Mucosal immunization with hsp70 and gB peptide results in systemic gB-specific 
cytotoxic T cell responses 
A standard cytotoxic T cell assay was used to examine the level of systemic CTL activity 
that was generated in each experimental group. Mice, as previously described, were 
immunized a total of 3 times i.n or i.p. with hsp70 and gB peptide. Five days after the 
final boost the spleen was removed and restimulated for 5 days in the presence of 
irradiated syngeneic splenocytes loaded with gB peptide. A standard Cr51 release assay 
was then performed to assess cytotoxic function. As seen in figure 1, both groups that 
received hsp70 coupled to gB peptide mounted robust CTL responses in comparison to 
control groups immunized with hsp70 and control peptide or gB peptide alone. At the 
highest effector to target ratio (50:1) mice i.n. immunized with hsp70 and gB peptide 
yielded a specific lysis of over 60%, while control mice given gB peptide alone showed 
less than 20% lysis. It is interesting to note that mice receiving i.n. hsp70 and SSIEFARL 
mounted slightly higher CTL activity in comparison to i.p. administered mice (60% 
versus 34% specific lysis). Mice given hsp70 and ova peptide yielded minimal killing 
(less than 10% ), regardless of the route of administration. 
Mucosal immunization with hsp70 and gB peptide grants protection against a lethal 
vaginal challenge with HSV-1 
In an effort to test if mucosal imm�zation with hsp70 and gB peptide was effective at 
controlling or preventing a vaginal HSV-1 infection i.n or i.p. immunized mice were 
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subjected to a lethal challenge (106 pfu) with HSV-1 McKrae, a highly virulent strain that 
often results in paralysis and death in immunized mice. Mice were immunized as 
previously described and then synchronized as described in the materials and methods 
prior to challenge. According to previous studies synchronization of the estrous cycle is 
an important factor for susceptibility to vaginal infection with HSV-1 [23]. Mice were 
vaginally challenged and scored for disease as described in materials and methods. As 
evident in figure 2, only mice that were immunized i.n with hsp70 and gB peptide were 
virtually completely protected from significant disease and death. Mice that received 
hsp70 and SSIEFARL i.p. demonstrated a reduced disease course and moderate 
resistance to encephalitis and death, as 66% of the mice fully recovered. Mice that 
received hsp70 and control ova peptide or mice that received gB peptide alone developed 
severe disease, and most, if not all, succumbed to infection in both control groups. 
Surprisingly, i.n. hsp70 and gB peptide immunized mice only developed extremely mild 
disease or none at all, and all mice were protected from death. 
Mice immunized mucosally with hsp70 and gB peptide secrete elevated levels of 
IFN-y in vaginal washings during challenge with HSV-1 
Throughout the challenge with HSV-1 McKrae daily vaginal washings were collected to 
examine IFN-y levels throughout the course of infection. Figure 3 shows that mice that 
had received hsp70 and gB peptide i.n. demonstrated higher initial levels (2-fold 
enhancement) ofIFN-y early on during infection and also mounted a delayed production 
of IFN-y (400 +/- 153 pg/ml), observed on day 4 p.i. which was completely absent in all 
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other groups. This delayed production of IFN-y is most likely attributable to infiltrating 
memory CDS+ T cells. The early enhanced IFN-y response in mice i.n. immunized with 
hsp70 and gB498-505 is most likely due to a combination of tissue residing effector 
memory CDS+ T cells or an elevated NK cell response in relation to the other groups. 
However, high NK cell responses were observed in all groups. 
Mucosal immunization with hsp70 and gB peptide results in an enhanced viral 
clearance rate 
We next set out to determine if such enhanced CDS+ T cell responses were capable of 
affecting the rate of viral clearance following a high dose mucosa! vaginal challenge with 
HSV-1 McKrae. Mice were synchronized with Depo-Provera as before and challenged 
with HSV-1 on day 4 after the final booster. Vaginal washings were then taken on each 
day to determine the level of virus present. As seen in table 1, Mice that were previously 
immunized i.n. with hsp70 and gB peptide were able to clear virus from the vagina at a 
slightly faster rate than in comparison to control groups. In addition, groups receiving 
hsp70 and gB peptide, i.n and i.p., were able to completely clear virus one day faster than 
control groups (4 days versus 5 days for control groups). This suggests that viral 
clearance rate is enhanced moderately following either mucosa! immunization or 
systemic immunization with hsp70 and gB peptide in comparison to hsp70 and control 
peptide or gB peptide alone. 
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Discussion 
The present study assesses the efficacy of mucosal immunization with hsp70 in 
conjunction with the immunodominant CDS epitope found in C57BL/6 mice from HSV-
1, gB 498-505 . In addition, the mucosal route of administration was compared to another 
systemic route, i.p. administration. These two vaccination approaches were then 
compared in their ability to generate systemic CTL activity, increase resistance to vaginal 
challenge, enhance vaginal cytokine levels, and enhance viral clearance rate. Results 
demonstrate that hsp70 coupled to gB498-505, regardless as to the route of 
administration, primes a systemic response in the spleen as measured by a standard Cr5 1 
release assay. In addition, it appears that i.n. administration of hsp70 and gB498-505 
leads to enhanced IFN-y levels in the vaginal lumen, faster clearance of virus, and 
elevated resistance to vaginal challenge. Enhanced levels of vaginal IFN-y may be a 
critical factor for the observed resistance to disease, and this has been carefully 
documented before [24] . It is also interesting to speculate upon the source of the 
enhanced early levels of IFN-g in vaginal washings (24 h). The source is most likely NK 
cells, which have shown to play a critical role in the early control ofHSV [25], or 
effector memory CDS T cells. More interesting, it appears that mucosa! administration of 
hsp70 and gB498-505 is more effective than i.p. administration in reference to the ability 
of each regimen to protect against vaginal challenge. 
Several reports have demonstrated the efficacy ofhsp70 and peptide to act as an 
effective vaccine against viral infection, most notably in the LCMV system by the Welsh 
group and studies in our own lab [8,22]. However, all hsp70 strategies to date have 
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utilized either i.p., intradermal (i.d.), or s.c. immunization routes. Our own group has 
demonstrated that i.p. immunization with hsp70 and gB498-505 generates potent acute 
responses, but these responses decay over time in comparison to groups immunized with 
a recombinant vaccinia virus expressing gB498-505 [8]. This difference was most likely 
attributable to a lack of CD4+ T cell help during priming in the hsp70 groups, and 
additional work showed that the addition of cognate CD4+ T cell help was sufficient to 
greatly improve long-term responses [9]. In addition, studies from our own lab using 
CpG and gB498-505 also demonstrated a lack of long-term durability, as mice challenged 
in the memory phase showed reduced resistance to viral challenge [ 6]. It is likely that 
long-term protection would also diminish in mice mucosally immunized with hsp70 and 
peptide, much like that observed in earlier studies. Clearly, additional work is needed 
including possible CD4 epitopes, such as including recombinant full-length gB, to 
possibly enhance the acute as well as long-term memory response. Other possibilities for 
improvement include the use ofhsp70 and peptide as either a priming or boosting agent 
along with recombinant vaccinia virus expressing gB or plasmid DNA encoding gB. 
Prime-boost mucosa! vaccination against HSV-1, as previously demonstrated, was more 
effective when the recombinant vaccinia virus rather than plasmid DNA when used 
during the priming step rather than the boost [26]. Perhaps hsp70 and peptide approaches 
would also be more effective as a booster immunogen, especially since CD4+ T cell help 
may not be as essential during the booster stage. This concept is currently under 
investigation. In addition, further work is warranted to determine the effects upon 
maturation and migration that hsp70 exposure may exert upon respiratory DC, which are 
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typically resistant to maturation signals in comparison to other tissue compartments such 
as the spleen. 
Overall, this study is the first to investigate the possible use ofhsp70 as a mucosal 
adjuvant capable of priming protective cog+ T cell responses. In humans it has been 
demonstrated that COS+ T cell responses are closely linked to HSV control and clearance. 
Therefore, approaches stimulating immunity may prove beneficial in a clinical setting, 
especially since many HSV peptide epitopes for several common HLA Class I haplotypes 
have been discovered in recent years [1]. We demonstrate that hsp70 is indeed a safe, 
effective mucosa! adjuvant capable of inducing elevated IFN-y levels in the vagina in 
response to infection, enhancing viral clearance, as well as elevating systemic CTL 
activity and overall protection from disease. Additional work fully characterizing the 
nature and level of the COS+ T cell response within mucosa! tissues should add further 
support for this novel, promising approach. 
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50 : 1  
II i.n. Hsp70+SIINFEKL 
� i.n. SSIEF ARL 
--0- i.n. Hsp70+SSIEFARL 
--f:s-- i.p. Hsp70+SSIEFARL 
25: 1  
E:T Ratio 
12 : 1  
Figure 1 .  Spleen CTL activity following systemic or mucosa/ Hsp 70+SSIEF ARL 
immunization 7d after the final boost using a standard 4 h 51Cr release assay 
reveals enhanced levels of cytotoxicity in hsp70 mucosally immunized mice. 
Various E:T ratios were performed using MC38 target cells loaded with gB498-
505. 
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Table 1 .  Viral Clearance After Vaginal Challenge 
with HSV- 1 McKrae ( 106 pfu) 
Day Grl 
1 4.3x105 
2 7x104 
3 l .9x103 
4 lx103 
5 3x103 
Gr2 Gr3 
lxl05 6.3x104 
4x104 2. lx104 
3x103 2.5x103 
6.3x102 2x102 
l .5x103 0 
Grl-i.n. Hsp70+SIINFEKL 
Gr2-i.n. SSIEF ARL 
Gr3-i.n. Hsp70+SSIEF ARL 
Gr4-i.p. Hsp70+SSIEF ARL 
96 
Gr4 {PFU/ml} 
2.6x105 
4X10 
l .3x.103 
5x102 
0 
= 
10 II i.n. Hsp70+SIINFEKL - i.n. SSIEF ARL 
-0- i.n. Hsp70+SSIEF ARL 
7.5 -
--1:r- i.p. Hsp70+SSIEF ARL 
5 -
400 pg/ml (i.n. 
hsp70+SSIEFARL) 
2.5 -
vs. 0 (all others) 
0 -J.----------------
24 48 72 96 
Hours post infection 
Figure 2. Enhanced levels of IFN-y are secreted in response to HSV-1 
McKrae vaginal infection from mice mucosally immunized with hsp 70 
and SSIEF ARL. Data were obtained from vaginal washings performed 
every 24 h with PBS followed by ELISA for detection ofIFN-y. 
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Figure 3. Mice that received mucosa/ administration of hsp 70 and SSIEF ARL 
were resistant to vaginal challenge with HSV-1 during the acute phase 
response. Mice were vaginally challenged with HSV-1 McKrae strain (106 pfu) 
on d5 following the final treatment. Grading was performed daily as follows: 1 )  
mild vaginal inflammation, 2) moderate inflammation and swelling, 3 )  severe 
inflammation, ulceration, and hair loss, 4) paralysis, and 5) death. 
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Part IV. 
Binding of an Anti-DNA Antibody to Plasmid DNA Enhances 
Cytotoxic T Cell Immune Responses 
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Abstract 
Even though it has been over a decade since genetic vaccines were first introduced they 
have failed to generate effective responses in primates, despite strong observed responses 
in rodents. Therefore, a number of approaches have been investigated to improve DNA 
vaccine efficacy. In this study we describe a novel method for improving plasmid DNA 
delivery to antigen presenting cells by first binding an anti-DNA antibody to the plasmid 
DNA. Antibody-bound plasmid DNA is most likely taken up more efficiently via Fe 
receptors, thereby leading to higher levels of transcription and enhanced presentation to T 
cells. This antibody-bound plasmid DNA vaccine regimen, in comparison to plasmid 
DNA alone, also leads to an enhancement of the immune response to the encoded antigen 
as measured by IFN-y secreting cells and cytotoxic T cell activity. 
Introduction 
Following the initial discovery that protective immunity and cytotoxic T cell 
responses (CTL) could be generated in vivo by plasmid DNA injection [ 1 ] ,  many groups 
have used this approach in a multitude of vaccine candidates [2-7] . Despite success in 
rodents, genetic vaccination in primates has never reached the same level of efficacy, 
primarily due to low immunogenicity. It has been well documented that DNA given 
intramuscularly (i.m.) or intradermally is primarily taken up by muscle cells or 
keritinocytes, respectively. However, these cell types are unable to prime immune 
responses. It is currently assumed that these cells take up the DNA, express the encoded 
1 00 
protein, and then transfer this protein to professional antigen presenting cells (APC), such 
as dendritic cells [5,8]. 
A number of strategies exist that improve the potency of DNA vaccines. One way 
to enhance DNA vaccine potency involves modification of the vector to enhance antigen 
presentation (which may involve intracellular targeting or targeting to other cell types) 
[3,9, 10]. Another general strategy deals with improving delivery of plasmid DNA, 
thereby enhancing transfection efficiency. Popular variations of this strategy include the 
use of recombinant bacteria such as salmonella [11], the use of bacterial ghosts [12], M 
cell targeting of plasmid DNA via attachment to a reoviral protein (thereby enhancing 
mucosal DNA delivery) [13], cationic microparticles [14], and in vivo electroporation 
[ 15]. In essence, each of these strategies attempts to increase the relative number of cells 
that take up the plasmid DNA. A third approach for improving DNA vaccine potency 
involves the inclusion of genetic adjuvants (such as cytokines, chemokines, or 
costimulatory molecules), either as a gene or a coadministered agent [ 16-19]. In this 
study we investigate the potential of using anti-DNA antibody to target plasmid DNA to 
APC, such as dendritic cells and induce cell-mediated immunity. Since DC express 
receptors for the Fe portion of lgG (Fcyrs), which mediate internalization of antigen-IgG 
complexes and promote efficient presentation of these internalized antigens, we 
investigated if this process might also be able to enhance delivery and uptake of plasmid 
DNA. In addition, Fe receptor binding has been shown to lead to the maturation of DC, a 
process that might further enhance the immune response to the encoded antigen [20]. 
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Materials and Methods 
Mice 
Four- to five-week-old C57BL/6 (H-i) mice were purchased from Harlan Sprague­
Dawley (Indianapolis, IN). In conducting the research described in this work we adhered 
to the Guide for the Care and Use of Laboratory Animals as proposed by the committee 
on care of Laboratory Animal Resources Commission on Life Sciences of the National 
Research Council. The facilities are fully accredited by the American Association for 
Accreditation of Laboratory Animal Care. 
Peptides 
The HSV gB ( amino acids 498 to 505) peptide SSIEF ARL and the chicken ovalbumin ( aa 
257 to 264) peptide SIINFEKL were synthesized and supplied by Research Genetics 
(Huntsville, AL) 
Cell lines 
Vero (African green monkey kidney cell line) was used for growing of viral stocks and 
MC38 was used as a target cell (C57BL/6 adenocarcinoma, H-i). All cell lines were 
cultured in Dulbecco's Modification ofEagle's medium (Mediatech, VA) supplemented 
with 10% heat-inactivated fetal bovine serum, 5 mg/L of gentamicin sulfate, and 2 mM L-
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glutamine. T cell stimulation assays were carried out in 25 mM Hepes buffered RPMI-
1640 media (Sigma, St. Louis, MO) containing 10% heat-inactivated fetal bovine serum, 
5 mg/L of gentamicin sulfate, 0.05 mM 2-ME, and 2 mM L-glutamine. 
MRSS-1 production and purification 
MRSS-1 is a B cell hybridoma which makes a mouse IgG3 isotype anti-DNA antibody 
(ATCC #HB-69, Manassas, VA) [21]. The hybridoma was grown in roller bottles in 
DMEM 5% FCS (Mediatech, Herndon, VA and Hyclone, Logan, UT, respectively). The 
cells were filtered out using Whatman paper (Middlesex, UK) and the supernatant was 
frozen at -20°C until a later date. The supernatant was then thawed and mixed 1:1 with a 
saturated ammonium sulfate solution and allowed to sit at 4 °C overnight for precipitation 
of immunoglobulins and other high-molecular weight proteins. The precipitated proteins 
were passed over a protein L column (Pierce, Rockford IL) to isolate mouse lg by affinity 
chromatography. The concentration of the antibody was determined by UV spectroscopy. 
Plasmid DNA preparation 
The plasmid pcDNA-gB was created as described by Manickan et al [22]. It was 
propagated in £. coli DH5-a cells and grown in LB broth (both Invitrogen, San Diego, 
CA) and purified with an Endofree PJasmid Mega kit (Qiagen, Valencia, CA). 
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DNA/ Antibody binding assay 
pcDNA-gB was bound to a standard ELISA plate (Coming, Acton, MA) at [DNA]=S 
µg/ml, lO0uVwell using ReactiBind (Pierce, Rockford, IL) to bind the DNA to the plate. 
MRSS-1 was then added at various concentrations. Negative control wells contained non­
specific mouse lgG (Southern Biotech Associates, Birmingham, AL). All wells were 
done in duplicate and the ELISA was performed as previously described [22] . 
T cell activation assay 
An in vitro T cell activation assay was performed by first allowing splenic adherent cells 
(splenocytes adhered to plastic tissue culture plates for 2 h @ 37°C and then washed, 
scraped, and counted), consisting mainly of macrophage and DC, to take up plasmid 
DNA (pcDNA-gB), express protein, and present processed peptides to T cells. Antigen 
sources were as follows: 0. 1 µg/ml of MRSS-1 anti-DNA antibody was incubated with 
0. 1 µg/ml ofpcDNA-gB for 1 h @ 37°C (total vol 100 µ1). This complex was then added 
to 500,000 (total vol 50 µl) splenic adherent cells in a 96 well U-bottom plate and 
allowed to incubate for 24 h 37°C, 5% CO2 • Plasmid DNA without antibody as well as a 
group with an irrelavent control antibody were also included. For a positive control 
adherent splenocytes were either transfected with the same amount of pcDNA-gB as 
above using Lipofectamine 2000 according to the manufacturer's instructions 
(Invitrogen), or gB498-505 peptide (1 µg/ml) was used. Following the 24 h incubation 
50, 000 (total vol 50 µ1) T cell hybridoma specific for gB498-505, clone 2E2 [23] 
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(provided by F. Carbone) were added and the incubation was continued for another 24 h. 
Supernatant was then collected and tested for IL-2 production by ELISA. 
ELISPOT 
ELISPOT assay for IFN-y secreting cells was performed as previously described, except 
for slight modifications [24]. Briefly, 96-well filter plates (Millipore HA) were coated 
with capture antibody for IFN-y (RA-6A2) (BD Pharmingen) ON @ 4°C (BD 
Pharmingen) (2 µg/ml) in PBS. Plates were then washed with sterile PBS and blocked 
with culture. media containing 10% FCS. Splenocytes from a single cell suspension were 
incubated at various effector:stimulator ratios. 105 irradiated, SIINFEKL or SSIEF ARL­
pulsed irradiated (3000 rads), syngeneic splenocytes were used as stimulators. Serial 2-
fold dilutions of effectors were then incubated with stimulators starting with 5 x 105 and 
ending with 6.25 x 104• 20 U/well of IL-2 was also added to the culture. Cells were then 
incubated for 48 h at 37°C, 5% CO2. Wells were then washed with PBS, followed by 
PBS-Tween. Biotin anti-mouse IFN-y (XMGI.2) (BD Pharmingen) (1 µg/ml in PBS 3% 
BSA) was then added to each well and incubated ON @ 4°C. Wells were then washed 
with PBS-Tween and streptavidin-conjugated peroxidase (Jackson Laboratories, Bar 
Harbor, ME) in PBS 3% BSA was added to each well (1 µg/ml) for 30 min @ 37°C. 
Wells were then washed with PBS-Tween and developed using 3-amino-9-ethylcarbazole 
(AEC) (Sigma) in 0.1 M acetate buffer pH 5.0, containing 0.05% H202. Reactions were 
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allowed to proceed for 10  min and were ended by extensive washing with dH2O. Plates 
were allowed to dry and then counted on a stereo microscope. 
CTL assay 
The CTL assay was performed as described earlier [24] . Briefly, effector cells generated 
after a 5 d in vitro expansion (with SSIEFARL-loaded, irradiated splenocytes) were 
analyzed for their ability to kill major histocompatibility complex (MHC)-matched 
antigen-presenting targets. The cells were mixed with the target at various ratios and 
incubated for4 h. The targets included 51Cr-pulsed MHC-matched SSIEFARL-pulsed as 
well as control SIINFEKL-pulsed MC38 target cells. Percent specific lysis was then 
calculated according to the following formula: 
100 x [ ( experimental release - spontaneous release)/ (maximum release - spontaneous 
release)] . 
ELISA 
ELISA was performed as previously described [24] . Briefly, 96-well EIA/RIA plates 
were coated with capture antibody for IL-2 (BD Pharmingen) ON @ 4°C (2 µg/ml) in 1 
M Na2HPO4. The wells were then washed with PBS-Tween and supernatant taken after 
24 h was added and the plates were incubated ON @ 4°C. For detection wells were 
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washed with PBS-Tween and biotin anti-mouse IL-2 (BD Pharmingen) (1 µg/ml in PBS 
3% BSA) was then added to each well and incubated for lh @ RT. Wells were then 
washed with PBS-Tween and streptavidin-conjugated peroxidase (Jackson Laboratories, 
ME) in PBS 3% BSA was added to each well (1 µg/ml) for 30 min @ RT. Plates were 
then washed and developed using ABTS (Sigma). ELISA readings were taken on an 
automated ELISA reader (SpectraMAX 340, Molecular Devices, Sunnyvale, CA). 
Immunizations 
90µg/mouse pcDNA-gB was complexed to lOµg/mouse MRSS-1 for 1 h @ 37°C. This 
preparation was then split in half and administered to both of the tibialis anterior muscles 
of the mouse on day 0. Negative controls included pcDNA-gB alone and pcDNA-gB + 
control mouse IgG (Southern Biotech Associates, Birmingham, AL). Both underwent the 
same incubation as the experimental preparation. Tibialis anterior administration of 106 
pfu recombinant vaccinia virus expressing gB (VV-gB) served as a positive control. 
Statistical analysis 
The data were analyzed by using a 2-tailed student's t test, and p values less than .05 
were deemed significant. 
107 
Results 
The anti-DNA antibody MRSS-1 specifically binds to plasmid DNA 
Initial experiments were first undertaken to determine if the MRSS-1 antibody could 
indeed bind to plasmid DNA encoding gB from HSV-1 . As can be seen in figure 2, 
MRSS-1 antibody was able to bind pcDNA-gB, which was used for coating of the plate, 
in a dose dependent manner. Binding reached a saturation point at approximately 1 
µg/ml. Control mouse IgG showed no significant binding to pcDNA-gB. 
MRSS-1 antibody binding to plasmid DNA enhances antigen presentation to T cells 
We next wanted to test if antibody-bound plasmid DNA could be more efficiently 
internalized into professional antigen presenting cells (APC), such as dendritic cells 
(DC), and the encoded gB be transcribed, translated, and presented to CDS+ T cells. To 
this end we employed a T cell activation assay using a T cell hybridoma generated from a 
transgenic mouse in which 9S% of the CDS+ T cells recognize gB498-505, the dominant 
Class I-restricted epitope in C57BL/6 mice [25] . Adherent splenoytes were first incubated 
for 24 h with MRSS-1 antibody bound to pcDNA-gB, pcDNA-gB only, control mouse 
IgG and pcDNA-gB, MRSS-1 alone, lipofectamine and pcDNA-gB, or gB49S-505 
peptide. After allowing 24 h for expression and presentation, the gB-specific T cell 
hybridoma (2E2) was added to each well and after 24 h supernatant from each well was 
analyzed for production ofIL-2. As depicted in table I, MRSS-1 bound pcDNA-gB lead 
to a 3 fold increase over pcDNA-gB alone in the amount ofIL-2 (48 versus 16  pg/ml). 
However, lipofectamine and pcDNA-gB, which is far more efficient, generated strong 
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production of IL-2, with levels exceeding 1 000 pg/ml. Only background levels of IL-2 
( 15-20 pg/ml) were detected with control mouse lgG + pcDNA-gB or MRSS-1 antibody 
alone. Despite a relatively low level of IL-2 production in comparison to lipofectamine or 
peptide, these data are promising and do suggest that MRSS-1 antibody might be 
facilitating the entry ofpcDNA-gB into APC via Fe receptor-mediated uptake. 
The anti-DNA antibody MRSS-1 ,  when co-delivered with plasmid DNA, increases 
the number of IFN-y responding CDS+ T cells 
We next wanted to assess the ability of anti-DNA antibody to enhance genetic 
vaccination. Plasmid DNA encoding gB was either injected alone or in combination with 
MRSS-1 anti-DNA antibody. After 8 days the spleen was removed and an ELISPOT 
assay was performed as described in materials and methods. As shown in figure 3, 
inclusion ofMRSS-1 lead to a significant (2-3 fold) enhancement ofIFN-y secreting gB­
specific T cells in comparison to mice immunized with pcDNA-gB. However, when 
compared to levels generated with a recombinant vaccinia virus encoding gB, levels were 
only modest in comparison. Control groups immunized with mouse IgG and pcDNA-gB 
did not demonstrate any significant increase in response over pcDNA-gB alone. In 
addition, MRSS-1 antibody administ�red without pcDNA-gB did not elicit a gB-specific 
response. 
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Addition of anti-DNA antibody to plasmid DNA vaccination increases cytotoxic T 
lymphocyte activity 
We next tested the cytotoxic capability of CD8+ T cells that were generated from 
immunization with either pcDNA-gB, MRSS-1 anti-DNA antibody along with pcDNA­
gB, or a control mouse IgG and pcDNA-gB. Vaccinia virus expressing gB was used as a 
positive control. Immunization with MRSS-1 only does not generate a significant CTL 
response (data not shown). As depicted in figure 4, addition of the anti-DNA antibody 
significantly increases (2 fold) CTL activity in comparison to immunization with plasmid 
DNA alone. At an effector:target ratio of 25: l, mice that were immunized with MRSS-1 
and pcDNA-gB showed 30% killing of target cells, while pcDNA-gB immunized mice 
only had 15% specific lysis. Mice immunized with control mouse IgG and pcDNA-gB 
mounted a similar level of killing as pcDNA-gB only mice, suggesting that IgG is not 
exerting a non-specific effect upon immune response induction. Mice immunized with 
VV-gB had a much higher level of killing, with over 50% specific lysis at the_ same 
effector:target ratio. 
Discussion 
Genetic vaccination, despite over a decade of study and steady improvements, 
still lacks the potency and duration of live viral infection. Various strategies have been 
adopted to improve the efficacy of plasmid DNA vaccination. Among these include 
vector modification to increase expression or the inclusion of additional CpG stimulatory 
motifs. Other approaches focus on improving the immune response by adding adjuvants, 
either as a gene or protein, such as inflammatory cytokines and chemokines [5,19] . Still 
110 
other strategies include efforts to improve delivery of the plasmid DNA to cells of 
interest. Most reports regarding this approach do not specifically target a specific cell 
population, but instead increase the overall transfection efficiency (most commonly of 
myocytes ). Examples include in vivo electroporation and cationic microparticle delivery 
of the DNA [14,15]. A recent study by the Pascual group was one of the first to attempt 
to target plasmid DNA to a particular cell type [13]. They used a protein from from 
reovirus, cr l ,that attaches to M cells. Attachment of this reoviral protein to plasmid DNA 
encoding HIV gp 160 greatly enhanced both humoral and cell-mediated mucosa! immune 
responses. Therefore, specific targeting of plasmid DNA to a critical cell type, such as 
DC, may prove advantageous for the generation of a protective response. 
In order to target pcDNA-gB to APC we used an anti-DNA antibody, MRSS-1, 
which is a non sequence specific antibody that binds structural regions of the phosphate 
backbone of DNA. MRSS-1 binds plasmid DNA and most likely improves the ability of 
plasmid DNA to be uptaken by APC, thereby increasing the level of gene transcription, 
translation and ultimately presentation of the foreign protein. This should then permit T 
cell activation, a process not observed in vitro with naked plasmid DNA. In addition, 
plasmid DNA immunizations often require several boosters to obtain measurable 
responses. Here we show that only one immunization is necessary to generate CD8+ T 
cell responses. This strategy presumably operates via Fe-mediated internalization of the 
DNA/antibody complex, thereby increasing the transfection rate of APC by specific 
targeting. Our results suggest that this approach also increases cell mediated immunity, as 
measured by the level of RSV-specific IFN-y secreting cells and specific cytotoxic 
activity. Since Fe-receptor internalization results in the targeting of material to 
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endosomes (and ultimately the Class II-restricted pathway), it is surprising that any 
material escapes to the cytosol. However, reports do exist demonstrating that material 
internalized via Fe receptors can reach the cytosol and lead to cross-priming, the 
activation of CD8+ T cells with exogenously obtained antigen [26,27]. If proteins can 
access this minor pathway perhaps plasmid DNA can as well. At the present it is not 
known which Fe receptor is responsible for the observed enhancement. Additional work 
will focus on determining the role of individual Fe receptors in this process by antibody 
blocking experiments, both in vitro and in vivo. In addition, this approach would ideally 
use a sequence specific anti-DNA antibody, which has been described [28], to avoid 
possible autoimmune reactions. Other critical factors to consider include the possible 
effects of antibody dependent cell-mediated cytotoxicity (ADCC), a process which may 
occur in vivo since DC may keep anti-DNA antibody (IgG3)/DNA complexes on their 
surface for a short period of time bound to CD 16 (Fey RIii), allowing for the possibility of 
NK cell-mediated lysis. Delivery of a maturation stimulus through binding of Fe 
receptors on the DC may also enhance immune responses, much like a general adjuvant 
[20]. This additional stimulus would only add to the pre-existing TLR9 stimulation from 
the CpG motifs of the plasmid DNA [29] . Work is currently underway to address the 
contribution and effect of Fe-mediated maturation on DC. In addition, we are 
investigating the relative impact of anti-DNA antibody/plasmid DNA vaccination upon 
gB-specific CD4+ T cell and antibody responses. However, the ultimate test of any 
vaccine candidate is challenge with the infectious agent of interest. Studies assessing the 
effect of this novel approach against a cutaneous HSV-1 infection are underway using a 
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zosteriform challenge model [22]. These additional experiments should reveal the overall 
effectiveness of this novel approach. 
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SSIEFARL presentation 
on MHC class I • 
APC 
(DC or macrophage) 
Figure 1 .  Schematic representation of plasmid 
DNA/anti-DNA antibody vaccination approach 
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Table 1 .  MRSS-1 antibody bound to pcDNA­
gB activates a T cell hybridoma specific for 
gB498-505 
Adherent Splenocytes loaded with: IL-2 (pg/ml) 
pcDNA-gB (0.5 mg/ml) 16 
pcDNA-gB (0.5 mg/ml) 
+MRSS-1 mAb (0.5 mg/ml) 48 
pcDNA-gB (0.5 mg/ml)+ 15 
mouse IgG (0.5 mg/ml) 
MRSS-1 mAb alone 17 
Lipofectamine + pcDNA-gB 1005 
gB498-505 (1 mg/ml) 1553 
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Figure 2. MRSS-1 antibody binds plasmid DNA 
(pcDNA-gB) in a dose dependent manner 
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Figure 3. MRSS-1 bound pcDNA-gB increases the number 
of IFN-r secreting cells during the acute phase response as 
measured by EL/SPOT 
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Figure 4. CTL Activity is enhanced in the 
spleen of mice immunized with pcDNA-gB 
and MRSS-1 anti-DNA antibody 
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